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The term adnexal mass refers to all cysts, tumors and tumor-like lesions originating in the 
ovary or the fallopian tube. Adnexal masses can be benign or malignant and can present 
at any age. Adnexal masses appear less frequent in children compared to women of 
reproductive age or postmenopausal women. Most is known about adnexal masses in 
postmenopausal women since the incidence of ovarian cancer is highest in that group.1   
EPIDEMIOLOGY
In 1971, a highly cited thesis was published by Lindfors that reported an incidence of benign 
and malignant adnexal masses combined of 2.6 per 100.000 girls each year. This was 
based on a Finnish cohort of 81 girls under the age of 14, which means that the majority 
were probably premenarchal girls.2 No incidence studies on adnexal masses in women of 
reproductive age have been published, but clinical experience suggests a higher incidence of 
adnexal masses in this population. Published incidence studies involve all age categories and 
include only malignant adnexal masses. These studies include large case series and cohorts 
based on cancer registries, and show a different and more diverse pattern of histology in 
the younger population. There is specifically a higher incidence of germ cell tumors.3-5
Adnexal masses are classified in over 100 diagnoses and the World Health Organization 
(WHO) classification of ovarian tumors is the most commonly used classification to 
categorize adnexal masses. In this classification ovarian tumors are classified according to 
their tissue of origin; epithelial lesions, germ cell tumors, and sex cord stromal tumors. 
Cysts and tumors of other origins are classified in this thesis as ‘other cysts, tumors and 
tumor-like lesions’.6
Epithelial lesions
Epithelial lesions are the most common ovarian lesions in adults and can originate from 
the surface-epithelium, the salpinges, or from endometriosis. These lesions are categorized 
in benign, borderline malignant and malignant lesions. Epithelial lesions can be divided 
in multiple histological subclasses; the main categories are serous (53%), mucinous (31%), 
endometrioid (6%), clear cell (3%), and translational cell tumors (3%).7 Epithelial tumors are 
less common in children, especially in premenarchal children.8
Germ cell tumors
Primitive germ cells from the embryonic gonad are the source of germ cell tumors. Most 
ovarian germ cell tumors are dermoid cysts or their solid counterpart mature teratomas, 
which are both benign. The most common malignant ovarian germ cell tumors are immature 
teratomas, dysgerminomas, yolk sac tumors, and mixed germ cell tumors.9 Germ cell tumors, 
benign and malignant combined, comprise 70% of all ovarian neoplasms in children and 
are therefore the most common ovarian neoplasm in this age group.10
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Sex cord stromal tumors
Sex cord stromal tumors contain all tumors derived from granulosa cells, theca cells or 
luteinized derivates from these cells. These tumors are less common than epithelial 
tumors or germ cell tumors. Sex cord stromal tumors can be categorized in benign tumors 
– with fibromas and thecomas being the most common – and malignant tumors, of 
which the  most common are granulosa cell tumors, both juvenile and adult, Sertoli-Leydig 
cell tumors, gynandroblastomas, and sex cord stromal cell tumors with annular tubules. 
Other tumors and ‘tumor-like lesions’
All other tumors and tumor-like lesions are combined in the last category. The most 
common benign lesions in this category are functional cysts such as follicle cysts and 
corpus luteum cysts, endometriotic cysts, and parovarian cysts. Malignant lesions are rare 
but include mostly lymphomas and metastasis from another primary tumor. 
Adnexal masses in children have mostly been described in relatively small case series or 
in large cohorts based on cancer databases.1, 11-15  The fact that there are only small case 
series indicates that adnexal masses are indeed rare in this population. Incidence and 
malignancy rates would be very helpful in the risk estimation and could probably be 
integrated in existing models. No large cohort including benign and malignant adnexal 
masses has been published in the last 40 years.
DAILY CLINICAL PRACTICE
In case of an adnexal mass in a girl, different medical specialties may be involved, including 
pediatricians, pediatric surgeons, pediatric oncologists, gynecologists and gynecologic 
oncologists. There are no clinical guidelines available on this topic. The background 
and experience of the consulted specialist may influence the choices in diagnostic 
techniques and surgical treatment, which leads to great diversity in the treatment of girls 
with adnexal masses. 
Diagnosis
Diagnostic tools which may be used to investigate an adnexal mass in children are 
menarchal status, symptoms, size of the tumor, ultrasound/MRI/CT characteristics and 
tumor markers. 
Menarchal status influences the chance of functional cysts and other adnexal masses 
related to the menstrual cycle, and thus menarchal status is important when diagnosing 
an adnexal mass and determining the risk of malignancy. Symptoms suggestive of a 
change in sex hormones, such as premature puberty or a changes in the menstrual cycle, 
can point to a hormone producing tumor such as a granulosa cell tumor. 
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Imaging studies provide us with the size and aspects of the tumor. Ultrasound is the 
imaging technique of choice and could be used to estimate size and compounds of 
the mass, while ultrasound Doppler can study blood flow to and within the tumor. 
All these characteristics are important to determine the origin and estimate the malignant 
potential of the mass. In case more detailed imaging is needed an MRI scan is the 
technique of first choice, it provides images with high detail without exposing the child 
to the radiation of  CT.16
The last important diagnostic technique is the estimation of tumor markers in blood. 
Tumormarkers are biomarkers made by the body in response to a malignancy or by 
the tumor itself. In adults, CA125 is the most extensively used tumor marker for ovarian 
cancer. In children α-fetoproteine (αFP), β human choriogonadotropin (β-HCG), lactate 
dehydrogenase (LDH) and inhibin are also important tumor markers.17  This difference in 
tumor markers is a direct result of the different histology of adnexal tumors found in 
children.
Test results can be interpreted on their own, but they can also be used in risk prediction 
models as described later on.
TREATMENT
Not all adnexal masses require treatment or follow-up. In case of a non-symptomatic 
follicle cyst or small cystadenoma in adolescence, there is no need for further follow-up. 
However in pre-puberty, or in case of a larger or more complex cyst, treatment or follow-up 
until the lesion stabilizes or disappears is needed.18 
Surgical treatment is indicated in large adnexal masses, symptomatic masses, or masses 
with a suspicion of malignancy.18 Surgical approach as well as procedure depend on the 
size of the adnexal mass and the risk of malignancy. Laparoscopic surgery is preferred over 
a laparotomy whenever possible, as this approach carries a lower risk of adhesion 
formation, and it is less invasive resulting in quicker recovery and a shorter hospital stay.19
The most important long term difference between the various surgical procedures is 
whether or not the ovary is removed. Ovary sparing procedures include cyst aspiration, 
cyst fenestration and cystectomy. Cyst aspiration, in which only the cyst contents are 
removed and not the cystic wall, is not recommended due to a high percentage of 
recurrence,20 and the diagnostic value of cytology is debated in the literature.21 
Cystectomy is the preferred procedure in benign adnexal masses, where the cyst including 
the cyst wall is removed while leaving vital ovarian tissue in situ.  
12
CHAPTER 1
Surgical procedures which remove the whole ovary are unilateral oophorectomy, bilateral 
oophorectomy and the total debulking surgery (in which all tumor, both ovaries, fallopian 
tubes, the uterus and omentum are removed). An oophorectomy can be done with or 
without removing the fallopian tube or salpinx (salpingo-oophorectomy). 
The unilateral salpingo-oophorectomy in case of normal contralateral ovary and tube is a 
fertility sparing procedure, but impairs a patient’s follicle reserve. Possible effects on future 
fertility are not totally clear yet, short term results of relative small studies indicate no 
difference in antral follicle count, pregnancy rates, or life births.22, 23 However the effect on 
age of menopause is unclear, and serum FSH concentration indicate these women might 
have a shorter reproductive life span.24 After unilateral oophorectomy, fertility can be 
threatened in case of future ovarian torsion or extra-uterine pregnancy which can require 
oophorectomy or salpingectomy of the remaining ovary. 
It is clear that a fertility sparing procedure, preferably an ovarian sparing procedure, is the 
first choice in children and women of reproductive age. The percentage of patients 
treated with an ovarian sparing procedure strongly depends on the specialty of the 
operating surgeon. Studies have shown that pediatric surgeons are more likely to remove 
the whole ovary, while gynecologic surgeons more often perform ovarian sparing 
procedures.25  It was unknown at the start of this thesis whether this was also the case 
in the Netherlands, earlier studies however recommend a multidisciplinary approach, 
in which a pediatric surgeon consults the gynecologist and vice versa.13
RISK OF MALIGNANCY
When an adnexal mass is diagnosed, the risk of malignancy should be estimated to 
determine the optimal diagnostic work-up and treatment protocol. The risk of malignancy 
differs per age group. 
Multiple risk models have been developed to estimate the risk of malignancy of an adnexal 
mass in adults. In the Netherlands the Risk of Malignancy Index (RMI) is implemented in 
daily clinical practice and most commonly used.26 Recently, new ultrasound based models 
such as the ‘Simple Rules’, the more detailed ‘Logistic Regression’ models LR1 and LR2 and 
the ADNEX model have been published by the IOTA group.27-29 These models have shown 
superior diagnostic accuracy over the RMI.30 However, all these models are based on an 
adult population, in which epithelial ovarian carcinomas are the most prevalent histological 
subtype.
13
INTRODUCTION AND THESIS OUTLINE
1
To estimate the risk of malignancy in a younger population, with a more diverse tumor 
histology and a different malignancy rate, a different risk estimation model is needed. 
For the pediatric population, only one model (Pediatric Risk of Malignancy Index) has 
been published, which included ultrasound based factors as well as clinical symptoms.31 
Another tool, published by Papic and colleagues was designed to confirm a benign tumor 
in children and includes ultrasound appearance and tumor markers.32
Another option in diagnosing the type of adnexal mass is by cytology of cyst fluid or 
biopsy of the mass. Studies investigating the accuracy of fine needle aspiration cytology 
(FNAC) differ widely in their conclusions and have been  performed in adult populations 
only.21 Besides the actual diagnostic accuracy of the test, the risk of spill of malignant cells 
is another important issue. It is unknown whether FNAC causes relevant cyst rupture or 
spill, but if it does this should be avoided according to Vergote et al who have shown that 
rupture of the ovarian capsule worsens the prognosis and should be avoided in primary 
surgery of malignant ovarian tumors.33 Two cases were described in which a FNAC 
procedure seemed to have caused metastases,34 and the same mechanism has been 
described in other tumors. For this reason, FNAC is being discouraged in the guidelines of 
the American College of Obstetricians and Gynecologists.35 The question remains 
whether FNAC can contribute to a less invasive treatment in a pediatric population.
OUTLINE OF THIS THESIS
This thesis describes the current diagnosis and treatment of girls with adnexal masses and 
methods to increase diagnostic accuracy of adnexal masses in children, adolescents and 
young women in order to optimize their treatment. The main questions for this thesis are 
listed below.
What is the incidence of adnexal masses in children, adolescents and women of 
reproductive age in the Netherlands? (chapter 2)
How were girls with adnexal masses treated at the Radboud university medical center 
Nijmegen the Netherlands in the last 15 years? (chapter 3)
What is the external validity of the Pediatric Risk of Malignancy Index in the Nijmegen 
patient group? (chapter 4)
What was the value of fine needle aspiration cytology of the adnexal mass in children in 
the Netherlands? (chapter 5)
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In chapter 6 we discuss the many factors involved in risk estimation, how to interpret 
them and how they affect treatment recommendations. This chapter also contains general 
recommendations for diagnosing and treating girls with an adnexal mass and some ideas 
for future research are discussed.  
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ABSTRACT
Objective: To provide an accurate incidence of adnexal masses in children and young 
women which can significantly improve the performance of current risk prediction models. 
Methods: We used the PALGA database, a nationwide network and registry of histo-
pathology and cytopathology, as the primary source of our study. Reports on ovarian 
histology of girls, years 1991-2014, and women aged 21-39, years 2011-2013, were included. 
Reports were labeled using the WHO-classification and classified as benign, borderline 
malignant, or malignant. Surgical procedure was scored separately.  
Results: Included were 11,595 patients. The incidence of adnexal masses increased 
exponentially with age, from 0.43 per 100.000 womenyears at age 1 to 152 per 100,000 
womenyears at age 35. A (borderline) malignancy was found in 898 (7.7%) patients, ratios 
between benign and malignant masses varied with age and were lowest in premenarchal 
children. Histology varied widely with surface epithelial tumors (35.1%), germ cell tumors 
(29.8%), and other cysts, tumors and tumorlike lesions (32.8%) being evenly distributed 
while sex cord stromal tumors were rare and only represented 2.3%. The proportion of 
malignancies was 6.3% in germ cell tumors while the type of malignant germ cell tumor 
was dependet on age. Oophorectomy was more often performed in the premenarchal 
age group and in women approaching the end of their reproductive age.
Conclusion: Our results show that adnexal masses in different age groups do not only 
differ in histological subgroups but also in malignancy rate which is of high value in 
presurgical risk evaluation. 
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INTRODUCTION
In children and adolescents adnexal masses are uncommon, with the incidence of 
neoplastic masses being estimated at 2.6 per 100,000 girls each year.1  Several retrospective 
studies have been published with patient numbers varying from less than 20 to over 
500 patients.2, 3 These populations mostly represent single centre series and present 
heterogenic distributions of the different histological subtypes with malignancy rates 
differing widely.4, 5 In women of reproductive age adnexal masses are a common 
phenomenon, displaying a great histologic diversity. The incidence of malignant adnexal 
masses in young women also increases with age.6
Large series on the descriptive epidemiology of adnexal pathology in children, adolescents, 
and women of reproductive age are however lacking. The only studies available with 
large data sets on adnexal pathology in children and women of reproductive age are 
based on cancer registers such as SEER and are lacking information on  benign masses.7-9 
In the Netherlands (total population 17 million)10 the annual incidence of ovarian cancer 
is approximately 1300, with a mortality of 1000 women per year.11 Considering this high 
mortality rate, oophorectomy may seem the best option when confronted with an 
adnexal mass. However fertility is a very important factor in young patients, so a thorough 
risk estimation should be made before surgery.
The aim of this study was to evaluate the distribution of adnexal pathology in girls (0-13), 
adolescents (14-20) and women of reproductive age (21-39) in the Netherlands over the 
last two decades and to provide data for use in future risk prediction models.
METHODS
We used the PALGA registry database, a nationwide network and registry of histopathology 
and cytopathology, as the primary source of our study. This registry covers all hospitals in 
the Netherlands and contains abstracts of every histopathological and cytopathological 
diagnosis made from 1990 onward.12 
The search was conducted over two different time periods for two different age groups. 
The first search included all girls and female adolescents under the age of 21 with a report 
on ovarian pathology from January 1991 to July 2014. The largest time period possible was 
used to include all diagnoses in this unique cohort with a low incidence of adnexal masses. 
This search provided 7933 excerpts from 6177 patients. For the second search we identified 
all female patients of reproductive age (21-39 years) with a report on ovarian pathology 
22
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between January 2011 and December 2013. This time period was selected to match the 
first search results in count to achieve a feasible number of reports to analyze, as all reports 
had to be individually classified according to the World Health Organization (WHO) 
classification of ovarian tumors by the reviewers since predefined diagnoses were not 
fully implemented in all time periods. The second search provided 10298 excerpts from 
8745 patients. More recent years were selected to limit the amount of reports with missing 
data. Patients without an adnexal mass were excluded.
Age, diagnosis, malignancy, side, surgical procedure, and the presence of torsion were 
extracted from each excerpt. Reports with missing data on surgical procedure were 
included in the tables and excluded from analysis of surgical procedure. Surgical 
procedures were divided in ovarian sparing and non-ovarian sparing procedures, since 
oophorectomy could have serious consequences for the future of children, adolescents 
and women of reproductive age. Ovarian-sparing procedures in benign masses were 
compared to ovarian-sparing procedures in malignant masses to compare the efficacy of 
the implementation of ovarian sparing surgery. In the absence of evidence classifying 
the cyst otherwise, benign simple cysts were classified as benign serous cysts. In neonates, 
however, benign cysts were classified as functional cysts, since most neonatal ovarian 
cysts are functional due to maternal estrogen, placental HCG, and fetal gonadotropins.13
The reports were linked to a diagnosis according to the WHO classification of ovarian 
tumors and classified as being benign, borderline or malignant.14 Reports were divided 
in four main categories: surface epithelial-stromal tumors, sex cord-stromal tumors, 
germ cell tumors, and other (i.e. other cysts, tumors and tumor-like lesions). Borderline 
malignancies were classified as malignant, when using a division in benign and malignant 
pathology. Masses were classified as unknown benign or unknown malignant if necroses 
due to torsion or chemotherapy prevented further classification of the mass. Reports 
with an inconclusive WHO classification were reviewed by a pathologist specialized in 
gynecologic pathology and classified according his conclusion.
Premenarchal status was assumed in all patients under 13, since this is the mean age of 
the first menstruation in the Netherlands.15
Data were collected by the AJH and LMJ. Database consistency was checked by drafting 
frequency and cross-tables; inconsistent records were rechecked in the original database.
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Data were analyzed using IBM SPSS version 22.0 statistical software. Descriptive statistics 
were used to calculate the age-specific proportion of the various histologic subtypes of 
adnexal masses. Furthermore, the age distribution of girls and young women 0 – 21 in 
1990-2014 and 21 - 40 years of age in 2011-2013 was extracted from CBS Statistics 
Netherlands in order to estimate the age-specific incidence rates of adnexal masses.16, 17 
Categorical data were analyzed using chi-square tests and one sample binomial tests 
where appropriate. Reported p-values are two-sided and results were considered 
significant if p < 0.05. Microsoft Excel 2007 was used to design the figures. The simple 
moving average over three years was used to design trend graphs displaying the 
incidence,  proportion of (borderline) malignancies, the proportion of various histologic 
subtypes, malignancies in germ cell tumors, and surgical procedures related to age. 
The simple moving average over five years was used to display surgeries in patients with 
a benign mass. Data on percentages over a total <5 were not included in analysis due to 
their limited value. Cubic splines were used to optimize the visual appearance of all graphs. 
The study protocol was approved by the scientific counsel and the privacy commission of 
PALGA. Because only anonymized data were used, no further ethical approval was 
required for this study. 
RESULTS
The searches provided 18,231 excerpts, representing 14,922 patients. Patients without 
adnexal pathology (n= 939), with other adnexal pathology than an adnexal mass (n= 1,210), 
without diagnosis (n=158) or with diagnoses based on cytology only (n=1,001) were excluded. 
Revisions from patients living abroad (n=19) were also excluded. Included were 11,595 patients. 
Incidence
The incidence of adnexal masses increased exponentially with age (Figure 1). The majority 
of the adnexal masses in children and women of reproductive age were benign, but 
malignancy occurred at any age. Incidence rates of adnexal masses varied between 0.43 
per 100,000 women per year at age 1 and 152 per 100,000 women per year at age 35. 
Incidence rates in premenarchal girls were very low. Benign cysts in girls less than a year 
old had an incidence of 5.70 per 100,000 girls per year, which droped steeply after the first 
year. The incidence of benign tumors increased with age, from 0.34 at age 2 to 4.38 at 
age 12. Borderline malignancies were very rare in premenarchal children and did occur 
in only five cases, which were all mucinous tumors. Malignant tumors had an incidence 
rate ranging from 0.04 to 0.85 per 100,000 girls (below 13 years of age) per year. 
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Malignancy
A (borderline) malignancy was found in 898 (7.7%) patients.  The proportions of benign, 
borderline malignant, and malignant adnexal masses varied between different age 
groups. The proportion of malignancy was highest in premenarchal girls, after the age of 
20 this proportion was steady around 2-4%. Borderline malignancies begin to appear in 
early adolescence and stay constant at 2-4% after that (Figure 2).
Histological diagnoses
In this cohort we found 37 different diagnoses, including unknown pathology due to 
ovarian torsion or chemotherapy. Diagnoses were evenly distributed between surface 
epithelial lesions (35.1%), germ cell tumors (29.8%), and other cysts, tumors and tumor like 
lesions (32.8%). Sex cord stromal tumors were rare, representing only 2.3% (Table 1).
Germ cell tumors predominated in premenarchal girls, after which the surface epithelial 
tumors represented the majority of the adnexal masses. At age 20 years and higher, other 
pathology increased, with the main diagnosis being endometriotic cysts.  Sex cord stromal 
tumors represented a significant part of the adnexal tumors in girls aged 1-8 (Figure 3). 
Figure 1   Incidence rates (log scale) of adnexal masses among 11,595 women in  
the Netherlands, 1991-2014.
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Germ cell tumors
Germ cell tumors were found in 3,458 (29.8%) patients, of which 217 (6.3%) were malignant. 
The proportion of malignancy in germ cell tumors varied with age and was higher in 
premenarchal girls, with a maximum between ages 6-14 years (Figure 4). The incidence of 
mature teratomas, the only benign germ cell tumor, increased with age and peaked 
around the age of 30 years, with a slight drop afterwards. Proportions of various types of 
malignant germ cell tumors differed in different age groups. Immature teratomas and 
endodermal sinus tumors occurred at all ages, although they were relatively more rare in 
girls under the age of 10. Gonadoblastomas, dysgerminomas, and mixed germ cell tumors 
were most common in children and adolescents under 21 years. Only one embryonal cell 
tumor was found, in a 13 year old girl, and two germ cell tumors NOS in an 8 year old and 
a 14 year old girl. Teratomas with malignant transformation did only occur at the age of 
28 and above (Figure 5).
Surgical procedures
Patients underwent a range of procedures, with oophorectomy and salpingo-oophorectomy 
accounting for 1,575 (13.6%) and 2,585 (22.3%) patients (Table 2). Oophorectomy or 
 salpingo-oophorectomy was performed in 3,512 (32.8%) patients with a benign mass 
and in 648 (72.2%) patients with a borderline malignant or malignant mass (p <0·001). 
Figure 2   Proportion of malignancy of adnexal masses among 11,595 women in  
the Netherlands, 1991-2014.
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Table 1   Diagnoses of adnexal masses in 11,595 women.
Diagnosis N (%)
Surface Epithelial cysts and tumors
Benign serous cyst
Benign mucinous cyst
Benign mixed cyst
Benign Brenner tumor
Borderline serous cyst
Borderline mucinous cyst
Sereus cystadenocarcinoma
Mucinous cystadenocarcinoma
Clear cell carcinoma
Endometroid adenocarcinoma
Malignant Brenner tumor
Sex cord stromal tumors
Fibroma/thecoma
Sertoli-Leydig cell tumor
Granulosa cell tumor, adult type
Granulosa cell tumor, juvenile type
Granulosa cell tumor NOS
Gynandroblastoma
Malignant sex cord stromal tumor NOS
Germ cell tumors
Mature teratoma
Mature teratoma with malignant transformation
Immature teratomas
Dysgerminoma
Malignant mixed germ cell tumor
Gonadoblastoma
Endodermal sinus tumor
Embryonal carcinoma
Malignant germ cell tumor NOS
Other cysts, tumors and tumor-like lesions
Functional cyst
Parovarian cyst
Endometriotic cyst
Myoma
Unknown benign pathology
Carcinoma NOS
Sarcoma
Lymphoma
Metastasis other malignancy
Unknown malignant pathology
4075 (35.1%) 
2482 (60.9%)
1088 (26.7%)
14 (0.3%)
6 (0.1%)
150 (3.7%)
212 (5.2%)
42 (1.0%)
62 (1.5%)
4 (0.1%)
12 (0.3%)
2 (0.0%)
264 (2.3%) 
168 (63.6%)
23 (8.7%)
7 (2.7%)
43 (16.3%)
13 (4.9%)
1 (0.4%)
9 (3.4%)
3458 (29.8%) 
3241 (93.7%)
10 (0.3%)
76 (2.2%)
57 (1.6%)
33 (1.0%)
8 (0.2%)
30 (0.9%)
1 (0.0%)
2 (0.1%)
3799 (32.8%)
1718 (45.2%)
217 (5.7%)
1673 (44.0%)
16 (0.4%)
74 (1.9%)
13 (0.3%)
2 (0.1%)
29  (0.8%)
48 (1.3%)
9 (0.2%)
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Figure 3   Proportions of histological subclasses of adnexal masses among  
11,595 women in the Netherlands, 1991-2014.
Figure 4   Proportions of malignancy in ovarian germ cell tumors among 
3,458 women in the Netherlands, 1991-2014.
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Figure 5   Proportions of different malignant ovarian germ cell tumors among  
217 women in the Netherlands, 1991-2014.
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Figure 5   Continued.
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When dealing with a benign mass oophorectomies were more often performed in the 
premenarchal age group, while ovarian sparing surgeries were more common in post- 
menarchal patients. In patients approaching the end of their reproductive age, the proportion 
of oophorectomies increased, and at age 37-39 years approximately half (49.7%) of 
the patients with a benign cyst or tumor was treated with an oophorectomy or salpingo- 
oophorectomy and not by an ovarian sparing procedure (Figure 6).
Ovarian sparing procedures for benign ovarian masses increased in recent years among 
patients under the age of 21 years (Figure 7). 
Table 2   Surgical procedures of adnexal masses of 11,595 women.
Surgical procedure Benign  
masses (%)
Borderline malignant  
and malignant masses (%)
Total (%)
Biopsy 796 (7.4%) 33 (3.7%) 829 (7.1%)
Cystectomy 4298 (40.2%) 75 (8.4%) 4373 (37.7%)
Salpingectomy 12 (0.1%) 0 (0.0%) 12 (0.1%)
Oophorectomy 1353 (12.6%) 222 (24.7%) 1575 (13.6%)
Salpingo-oophorectomy 2159 (20.2%) 426 (47.4%) 2585(22.3%)
Unknown 2056 (19.2%) 141 (15.7%) 2197 (18.9%)
Autopsy 23 (0.2%) 1 (0.1%) 24 (0.2%)
Figure 6   Percentage of oophorectomies in benign adnexal masses among  
8,641 women in the Netherlands, 1991-2014.
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DISCUSSION
In this study we analyzed excerpts from 11,595 pathology reports of patients aged 0 to 40 
years old. This revealed a subtle distribution of the different adnexal masses in children 
and younger women. The present cohort is unique, and especially the large number of 
pediatric cases is exceptional, since in previous studies pediatric patients and women of 
reproductive age formed a minority in larger cohorts. Because of our large sample size the 
proportions of malignancy could be studied as well as a balanced view of on relative 
proportions of different histological subtypes could be provided.
Malignancy
The proportion of (borderline) malignancies varied  from 1.6 to 47.1% depending on age. 
In the literature percentages of (borderline) malignancy vary from 3.7 to 25.2% in girls and 
from 5 to 10% in women at reproductive age.4, 18, 19 These inconsistencies are possibly due 
to differences in population and according inclusion biases, inclusion criteria regarding 
age will significantly influence the proportion of malignancies found, which is shown from 
our data. 
Surprisingly, age is no factor in existing risk calculations and models published.20-22 This is 
possibly due to age being a non-linear risk factor for malignancy, which makes it more 
Figure 7   Ovarian sparing procedures in benign adnexal masses among  
4574 women aged 0-20 in the Netherlands over the years 1991-2014.
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difficult to embed this factor in a risk prediction model. The absence of age as a risk factor 
may however have seriously diluted the validity and reliability of these models.
The relation between malignancy and age has been previously studied in smaller case 
series. Oltmann et al have reported a threefold increase in the risk of malignancy in the 
age group 1-8 years old.22 Our results were similar to those published by Oltmann et al. In 
adults, a decrease of the proportion of germ cell tumors was reported by Kunpalin and 
co-workers in a study including from 2002 till 2011, while our more recent data showed 
a slightly rising proportion of germ cell tumors in women of reproductive age compared 
to adolescents.19 This difference between adolescents and the older women may be 
explained by the different inclusion periods of the studies. Over the years, surgery for 
small and simple cysts has lightly decreased, a trend also promoted in the most recent 
national guideline.23 Germ cell tumors however are, because of their irregular structure on 
imaging, more often treated surgically, which may lead to an increased ratio of pathology 
reports on germ cell tumors versus epithelial cysts in more recent times. 
Surgical procedures
The percentage of ovarian sparing procedures in benign masses varied with age. In children 
oophorectomy was quite common, while the number of cystectomies increased while 
approaching the reproductive age. The percentage of ovarian sparing surgeries decreased 
again at the end of the reproductive age. We expect not only the risk of malignancy, 
but also fertility preservation, surgical expertise and the avoidance of early menopause to 
play a role in the decision whether to perform an ovarian sparing procedure.  
Reports were scored on a robust set of variables that were available in most reports, 
making the amount of missing data very low. Performed procedure was less often 
reported and missing in 17% of the cases, and the terms used to describe procedures 
varied between pathologists as well, which may have had an effect on the classification of 
surgical procedures. However we found no reason to assume that missing data or possible 
errors were not at random.
A limitation of this study is the gathering of data over two different time periods. Since the 
incidence of adnexal masses grows exponentially with age, it was not feasible to analyze 
data over a period of 24 years from all women aged 0-39. Therefore we chose to analyze 
data of 24 years for children and adolescents up to 21 and complement these data with a 
comparable sample size of women aged 21-39. Proportions of epithelial-stromal cysts and 
germ cell cysts and benign and malignant masses are probably not only due to the 
difference in age but also to the inclusion period. In view of the low incidence of adnexal 
masses in girls, this is the best available evidence.  
The data in this study presents a clear view of the proportion of malignancies as well as 
histology diagnoses of adnexal masses in girls and women at reproductive age. In view of 
the clinically relevant age dependence of the chance of malignancy and incidence of 
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histological subtypes, new risk prediction models need to be developed that include age 
as a risk factor. These risk models should be used preoperatively in daily clinical practice to 
optimize care for patients with malignant as well as benign adnexal masses. 
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ABSTRACT
Objective: To evaluate the diagnosis and treatment decisions made in children and 
adolescents with an adnexal mass.
Methods: This was a retrospective cohort study among patients under age 18 years who 
were diagnosed with or treated for an adnexal mass at the Radboud University Medical 
Center Nijmegen between January 1999 and October 2013. Age, signs and symptoms, 
laboratory results, imaging data, type of surgery including surgeon specialty, and 
histological diagnosis were analyzed. Published criteria for characterizing a mass as benign 
(Papic et al) were applied to the present data set. 
Results:  One hundred and eleven patients were included. The mean age of the patients 
was 10.2±5.6 years, ranging between 0 and 17 years. Ovarian masses were malignant in 28 
patients (25.2%). Surgical therapy was applied in 83.1% of the benign masses and in 100% 
of the malignant masses. Oophorectomy was performed in 46.4% of the benign masses. 
The presence of a gynecologist was the only factor that significantly lowered the chance 
of an oophorectomy in benign masses (odds ratio 0.14, 95% confidence interval: 0.04-0.47). 
Papic et al’s model had a sensitivity of 40.91% and a specificity of 100%.  
Conclusion: Malignancy rate among patients with adnexal masses in our cohort was one 
out of four patients. Most patients with an adnexal mass were treated surgically and 
oophorectomy was performed in almost half of the benign masses. The presence of a 
gynecologic surgeon protected against oophorectomy in benign cases. 
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INTRODUCTION
Ovarian masses in children are uncommon with an incidence of neoplastic ovarian masses 
estimated at 2.6 cases per 100.000 each year.1 Previous studies have found that malignancy 
rates in ovarian neoplasms in children ranged between 3.7-23.5%,2, 3 accounting for 1% of 
all female pediatric cancers.1, 4 While epithelial ovarian cancer is leading in the adult 
ovarian cancers, it only represents  1.9% of all childhood ovarian neoplasms.5 Germ cell 
tumors and sex cord stromal tumors are more common among children with ovarian 
neoplasms and have a much better prognosis.4 
The majority of the ovarian masses in children are thus benign. In the past it was common 
practice to perform a single-sided oophorectomy in case of an ovarian mass or ovarian 
torsion in children. No surgeon wanted to risk the incomplete removal of a malignancy 
and torsed ovaries were already considered lost. Papic et al reported an increased rate of 
ovarian sparing procedures in recent years, but also pointed out that still too many 
unnecessary oophorectomies were performed.6 
In this study, the diagnoses and treatments of patients with an adnexal mass who had 
presented at our academic hospital were evaluated. We aimed specifically at identification 
of preoperative factors that influenced the decision for an ovarian-sparing procedure and 
related this to final histological results. 
MATERIALS AND METHODS
This was a retrospective cohort study. Patients were included in case they were diagnosed 
with or treated for an adnexal mass at the Radboud University Medical Center Nijmegen, 
a large university hospital in the Netherlands, between January 1999 and October 2013. 
Patients were excluded in case they were over 18 years of age at the day of their first 
consultation for an adnexal mass. Patients were identified using four different sources: the 
national registry of histopathology and cytopathology (PALGA) database, the registration 
codes for health insurance reimbursement (DBC/DOT-codes G16 and M16: benign and 
malignant ovarian pathology) and lists of patients kept by the pediatric surgery department 
and the gynecology department. There are no guidelines on the referral or treatment of 
these patients at our hospital. Due to the retrospective design, no ethical approval was 
required for this study. Exception from ethical approval was confirmed by our institutional 
review board.
Data were extracted from electronic and paper hospital patient records, including imaging 
reports, laboratory results, operation records, pathology reports and medical correspondence. 
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The following data were collected; age at presentation, menarchal status, presenting 
signs and symptoms, lab results including tumor markers (α-fetoprotein (αFP), β-human 
chorionic gonadotropin (β-HCG) or lactate dehydrogenase (LDH)), results from imaging 
examinations, type of surgery performed and histological diagnosis. Data were collected 
by the first author, after which data of 10% of the patients were validated by the last 
author. Database consistency was checked by drafting frequency and cross tables, 
inconsistent data were rechecked in the original patient files. 
Adnexal masses were divided in benign and malignant masses, based on the histo-
pathological diagnosis. Benign masses could be non-neoplastic (including simple cysts, 
pseudo cysts, para-ovarian cysts, torsed or enlarged or other ovaries without histological 
pathology), or neoplastic (including mature teratomas and cystadenomas). Simple cysts 
contained all follicular cysts and cysts described as ‘simple cyst’ or ‘cyst’ by the treating 
physician or pathologists without contradictory evidence stating otherwise at diagnoses 
or follow-up. The simple cysts group also includes patients with follicular cysts, which 
were not operated on and were therefore without histological confirmation, but also without 
contradictory evidence. Malignant masses consisted of all malignant and borderline 
tumors, tumors with malignant potential such as partially immature teratomas or masses 
that proved to be malignant in the clinical course over time. 
We applied the set of criteria to predict a benign mass as reported by Papic et al6 to our 
data set. Patients who satisfied the following criteria were selected: size of the mass 
< 10cm on ultrasound (US), no solid components on US and no positive tumor markers 
(αFP, βHCG and LDH). Although Papic et al used the preoperative mass size as well as 
mass size in surgery or histology, we used measurements on ultrasound imaging to 
determine the size and aspect of the mass, as this was better reported on imaging than 
during surgery or histology in the present data set. 
Statistical analysis was performed using IBM SPSS version 20.0 statistical software. 
For analysis of continuous data we used independent samples Mann-Whitney U tests for 
non-normally distributed variables. Categorical data were analyzed using chi-square tests. 
In tables with one or more variables lower in number than 10, a Fisher exact test was used 
instead of a chi-square test. Predictive factors were selected using uni- and multivariable 
binary logistic regression analyses. In the multivariable analysis, variables with a univariate 
p-value of < 0.25 were entered, with a maximum of three to prevent overfitting of the 
model. Highly correlated variables were not entered in the same regression model. 
Reported p-values are two-sided and results were considered significant at P < 0.05. 
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RESULTS
In total 144 patients were identified, of which 29 were again excluded for not having an 
adnexal mass. In 4 patients, no medical records could be retrieved and they were therefore 
excluded, leaving 111 patients included for analysis. Age ranged from 0 days to 17 years, 
with a mean age of 10.2 ± 5.6 years at the time of their first consultation at our hospital. 
Fifty-eight (52.3%) patients were premenarchal.
The frequency of histological subtypes of ovarian masses is shown in Table 1. No difference 
was found in the age at presentation between patients with benign masses (9.8 ± 5.9 yr) 
and patients with malignant masses (11.6 ± 4.4 yr; p = 0.18). 
Table 1   Final diagnosis in 111 patients.
Final diagnosis N (%)
Non-neoplastic benign masses
Normal ovaries
Simple cyst
Pseudo cyst
Parovarian cyst
Auto-amputation
Torsion
Neoplastic benign masses
Mature teratoma
Cystadenoma
Neoplastic malignant masses
Immature teratoma
Granulosa cell tumor, adult type
Granulosa cell tumor, juvenile type
Mixed germ cell tumor
Dysgerminoma
Mucinous borderline tumor
Mucinous cystadenocarcinoma
Sertoli-Leydig cell tumor
Yolk sac tumor
Embryonal cell carcinoma
Sex cord stromal tumor
45 (40.5%)
1 (0.9%)
26 (23.6%)
3 (2.7%)
5 (4.5%)
3 (2.7%)
7 (6.3%)
38 (34.2%)
32 (28.8%)
6 (5.4%)
28 (25.2%)
5 (4.5%)
2 (1.8%)
4 (3.6%)
3 (2.7%)
7 (6.3%)
2 (1.8%)
1 (0.9%)
1 (0.9%)
1 (0.9%)
1 (0.9%)
1 (0.9%)
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Abdominal pain was the most frequent presenting symptom, present in 67 (60.4%) 
patients. Patients with a malignant mass were more likely to present with abdominal 
distension or a palpable mass in the abdomen (66.7% vs 24.1%; p < 0.001 and 76.9% vs 
32.5%; p <0.001). Sex hormone related symptoms were also more frequent in patients with 
a malignancy (28.6% vs 6.0%; p = 0.003). The adnexal mass was an incidental finding in 
11 patients with a benign mass and was found antenatally in 13 patients. All incidental 
findings were the result of imaging performed for other reasons, such as diagnosis or 
follow-up of another condition. None of the incidentally or antenatally masses found were 
malignant. 
US was performed in 99 (89.2%) patients, a CT-scan was performed in 30 (27.0%) patients 
and  MRI was used in 34 (30.6%) patients. One patient had both a CT-scan and a MRI. 
The imaging techniques used are shown in Table 2. Patients with a malignant mass 
were more likely to have had a CT-scan or MRI compared to patients with a benign mass 
(82.1% vs 48.2%, p = 0.002). Malignant masses had a greater diameter on preoperative US 
than benign masses and a solid mass was more likely to be malignant than a cystic mass 
(Table 2).
Surgery was performed in 69 patients (83.1%) with a benign mass and in 28 (100%) with 
a malignant mass. Eleven (15.9%) patients needed a second operation and 3 (4.3%) 
patients a third operation. In the further analysis only the first operation was included. 
A gynecologist was present at 51 (52.6%) of the operations. The presence of a gynecologist 
was strongly related to menarchal status and patient age, but not with laparoscopy, 
maximum diameter of the mass or torsion (Table 3). 
Table 2   Ultrasound characteristics of malignant and benign masses.
Benign Malignant p-value
Max diameter lesion: mean ± SD 7.7 ± 4.9 cm 12.2 ± 5.2 cm 0.001
Cystic: N (%) 47 (59.5%) 4 (20.0%) 0.002
Mixed: N (%) 26 (32.9%) 11 (55.0%) 0.077
Solid: N (%) 3 (3.8%) 4 (20.0%) 0.029
Data with a significant p-value are made bold.
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A salpingo-oophorectomy or oophorectomy was performed in 56 (50.5%) patients, patients 
with a benign mass had a (salpingo-)oophorectomy in 32 (46.4%) cases. Cystectomy was 
performed in 32 (33.0%) patients, 9 (9.3%) patients underwent other procedures such as 
aspiration, detorsion, tubectomy or had a diagnostic laparoscopy without further surgery. 
Surgery was performed laparoscopically in 37 (53.6%) patients with a benign mass and 
in 3 (10.7%) patients with a malignant mass. Surgical staging was performed in 16 (57.1%) 
patients with a malignant mass. 
Torsion was present in 29 patients of which 27 patients (93.1%) had a benign mass. 
Oophorectomy was performed in 16 torsed benign masses (55.1%) and both torsed 
malignant masses (100%). In 7 cases of torsion (24.1%) no other ovarian pathology was 
found. Oophorectomy was less often performed in the last five years compared to 
previous years (30.0% vs 79.9%, p = 0.017). Three patients presented with auto-amputation 
of a torsed ovary. Twenty-three patients (79.3%) diagnosed with torsion presented with 
abdominal pain, of which 13 (56.5%) had abdominal pain for less than a week.  
To determine the factors associated with oophorectomy in benign cases, we calculated 
the risk of oophorectomy for multiple variables in the patients who had surgery for benign 
disease. The results of univariate and multivariate regression analyses are shown in Table 4. 
In univariate analysis premenarchal status was associated with oophorectomy. The presence 
of a gynecologic surgeon was strongly associated with a reduced probability of 
oophorectomy. Presenting symptoms, maximum diameter of the mass, torsion and use of 
laparoscopy had no significant influence on the probability of an oophorectomy being 
performed in benign masses. In the multivariate analysis torsion and a maximum diameter 
>6 cm were associated with a higher number of oophorectomies, while the presence of 
a gynecologic surgeon was again associated with a lower probability of oophorectomy 
(Table 4).
Table 3   Surgeon specialty.
Gynecologist  
present
No gynecologist  
present
p-value
Patients N (%) 51 (52.6%) 46 (47.4%) 0.614
Mean age (years) 13.8 6.3 < 0.001
Premenarchal patients1 N (%) 13 (25.5%) 40 (88.9%) < 0.001
Laparoscopy N (%) 20 (39.2%) 20 (43.5%) 0.685
Max diameter >6 cm N (%) 37 (72.5%) 31 (67.4%) 0.659
Torsion N (%) 16 (31.4%) 13 (28.9%) 0.827
1 Menarchal status was unknown in one patient in the group ‘No gynecologist present’.
Data with a significant p-value are made bold.
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We applied the set of criteria found by Papic et al to predict benign masses to the present 
dataset.6 Out of the 111 patients, US data were available on 84 patients (75.7%) of which 
66 had a benign mass (78.6%). Thirty-two patients had a mass < 10cm with no solid 
components, of which 27 had no positive tumor markers (αFP, βHCG and LDH). 
The sensitivity was 40.9% (95% CI: 29.0-53.7%) and the specificity was 100% (95% 
CI:81.3-100%). In this group, 2 laparotomies and 7 oophorectomies (of which 5 due to 
torsion) might have been avoided in case the model had been applied preoperatively. 
DISCUSSION
In this study we analyzed the diagnoses and surgical treatment of 111 pediatric patients 
with an adnexal mass. The final diagnosis was benign in 74.8% and malignant in 25.2%. 
Girls with benign masses had an oophorectomy in almost half of the cases, and the 
probability of an oophorectomy strongly decreased when a gynecologist was involved in 
the operation.
Table 4   Odds ratios of oophorectomy in patients with a benign ovarian mass who 
underwent surgical therapy.
Variable Odds ratio1 95% CI2 p-value1
Univariate estimates
Premenarchal 5.31 1.86-15.17 0.002
Pain 0.70 0.26-1.88 0.481
Palpable mass 1.44 0.54-3.79 0.465
Pain+palpable mass 1.42 0.47-4.26 0.533
Max diameter (cm) 0.99 0.90-1.08 0.780
Max diameter >6 cm 2.42 0.89-6.61 0.085
Laparoscopy 0.47 0.18-1.24 0.128
Torsion 2.52 0.93-6.83 0.069
Gynecologic surgeon 0.19 0.07-0.54 0.002
Multivariate estimates
Max diameter >6 cm 4.32 1.25-14.88 0.020
Torsion 3.41 1.06-10.96 0.035
Gynecologic surgeon 0.14 0.04-0.47 0.001
1 Odds ratio and p-value were calculated using binary regression analysis.
2 CI = confidence interval. Data with a significant p-value are made bold.
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Despite of the retrospective design of this study we managed to include over a 100 
patients in this case series, which is a strength of this study. Most studies with comparable 
patient numbers have only included surgically treated patients,2, 8 while our study included 
all pediatric patients with an adnexal mass. Our strategy may reduce bias in this small 
population. On the other hand the retrospective design inevitably causes inclusion bias 
and missing data. Patient inclusion was made as complete as possible by using multiple 
sources, but patients who did not undergo surgery might have been missed, as they were 
more difficult to identify. This means the real incidence of benign cysts is possibly higher 
than described, and the malignancy rate may be somewhat overestimated in our 
population. 
Histological patterns were overall consistent with the existing literature. The only exception 
was the higher incidence of granulosa cell tumors, which was 21% of all malignancies, 
while in previous studies sex cord stromal tumors represent 5-8% of all malignancies.4 
Torsion was related to oophorectomy, which was also found in previous studies.7, 9 
Literature on saving the ovary, even when it appears to be necrotic, is available since 1993 
including long-term follow-up.10, 11 The oophorectomy rate may be significantly lowered 
when applying this knowledge in clinical daily practice.
The criteria as defined by Papic et al to predict benign masses were developed based on 
data collected preoperatively as well as postoperatively.6 In the present study we 
performed external validation of the data in a preoperative setting. While Papic excluded 
infants, we have included all age groups, as well as para-ovarian cysts and torsed ovaries. 
Negative scores on all of the criteria resulted in a 100% benignancy rate in the present 
population, which would have changed policy into a more sparing operation in 7 cases. 
The sensitivity of this model however was only 41% (CI: 29-54%) which indicates that there 
is still room for improvement of risk models. 
Focusing on oophorectomy we found that the presence of a gynecologic surgeon was 
significantly associated with a reduced probability of oophorectomy in benign masses 
(OR = 0.14), a finding that confirms the results of others.7, 9 Fear for malignancy and a 
relative lack of experience with adnexal pathology of pediatric surgeons could be relevant 
factors.12 With new insights in fertility in young women with a single ovary, and a trend 
towards ovary-sparing surgery in ovarian torsion, ovarian surgery in pediatric patients has 
become more conservative over the years. This trend has also been described in case 
series with single specific ovarian masses such as teratomas.13 A unilateral oophorectomy 
does not sterilize the patient, but it could impair future fertility and future options in case 
of a contralateral ovarian problem.14 Furthermore, van Dorp et al showed that lower 
anti-mullerian hormone (AMH) levels have been found in these patients after one-sided 
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oophorectomy, which could indicate they have less ovarian reserve.15 There may however 
be a bias in our conclusion, since gynecologists may have been asked more often by the 
pediatric surgeon to assist in an intended ovary sparing operation.
When reading the recent literature our clinic seems to struggle with the same difficulties 
as other medical centers treating adnexal masses in children.2, 5 In line with others and the 
data available from this study, we would recommend treatment in a multidisciplinary 
team when dealing with adnexal masses in children. The experience of pediatric surgeons 
with these young patients and the experience of gynecologists with adnexal pathology 
and minimal invasive surgery of the ovary should be combined. 
In conclusion the results from the present study may be regarded as one further step to 
assist pediatric surgeons and gynecologists in the improvement of their decision making 
regarding adnexal masses in children and adolescents. Over the recent 10 years, ovary 
sparing surgery has increased. The criteria of Pavic et al reliably identify benign disease in 
approximately one third of patients with adnexal mass. 
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ABSTRACT
Objective: This study aimed to validate the Pediatric Risk of Malignancy Index (PRMI) as 
previously published. 
Design: External validation study.
Setting: Academic hospital: Radboud University Medical Center.
Population or sample: Female pediatric patients under the age of 18 diagnosed with, 
or treated for, an adnexal mass between January 1999 and October 2013.
Methods: Information was collected on diagnosis, presenting symptoms and signs and 
imaging characteristics. The PRMI was calculated for each patient. Sensitivity, specificity, 
positive- and negative predictive values were calculated and the results were visualized 
using a receiver-operating-characteristic-curve (ROC-curve). 
Main outcome measures: Histological diagnosis, discriminative performance using the 
area under the curve (AUC) of the receiver operating characteristic and sensitivity and 
specificity.
Results: Seventy-eight patients were included with a median  age of 12  years. A malignant 
mass was found in 17 patients (21.8%). The PRMI with a cut-off value of 7 resulted in a 
sensitivity of 70.1% (95% CI: 44.1-89.6%) and a specificity of 85.3% (95% CI: 73.8-93.0%). 
The area under the ROC-curve was 0.868 (95% CI: 0.756-0.980). 
Conclusions: The PRMI showed less discriminative capacity than originally published, but 
its performance was still good. However, further prospective validation studies are needed 
to define whether the model is useful in daily clinical practice. 
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INTRODUCTION
The incidence of neoplastic ovarian masses in children has been estimated at 2.6 cases per 
100.000 girls each year,1 which makes them uncommon in this population. The malignancy 
rates in previous studies have ranged from 3.7-23.5%,2, 3 accounting for 1% of all female 
pediatric cancers.4, 5 The histology in girls differs markedly from adults, and rare tumor 
types are more common than in adult women.6 This can make the preoperative 
assessment of adnexal masses a complex puzzle. There is more heterogeneity and 
generally less clinical expertise regarding the imaging of masses in girls as compared to 
adults. Malignancies represent a significant part of the ovarian masses in children and 
these masses should always be treated respecting oncologic guidelines, but on the other 
hand most of the ovarian masses in children will turn out to be benign. As a result, 
preoperative risk assessment of ovarian masses is important in view of prognosis, but at 
young age, preserving fertility also plays an important role in all cases. 
Various models have been developed to preoperatively predict ovarian cancer in adults, 
and most models have been externally validated in different adult populations,7 but as 
such are not applicable in a pediatric population For girls, only one model has been 
developed to predict the possibility of malignancy in an ovarian mass: the Pediatric Risk of 
Malignancy Index.8 The PRMI is based on three variables: the maximum solid diameter of 
the mass on imaging, flow or enhancement in a septum or at the base of a solid papillary 
formation and the presence of sex hormone related symptoms. In the original paper from 
Loh  and co-workers, the PRMI with a cut-off level of ≥ 7 had an overall sensitivity of 90.9% 
and a specificity of 98.5%, which were promising results. The PRMI has been developed in 
an Asian population, in girls under the age of 18. In the present study the model was 
externally validated in a retrospective cohort, in a mainly Caucasian population. 
METHODS
To validate the PRMI, a cohort of female patients under the age of 18 years, treated for an 
adnexal mass at the Radboud University Medical Center between January 1999 and 
October 2013 was selected. Patients were identified using four different sources: the 
national registry of histopathology and cytopathology (PALGA) database, the registration 
codes for the reimbursement by health insurance companies (DBC/DOT-codes G16 and 
M16: benign and malignant ovarian pathology) and patient lists kept by the paediatric 
surgery department and the gynecology department. 
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Data on symptoms, imaging data, histology and final diagnosis were collected from the 
medical files. Symptoms were considered sex hormone specific when including menstrual 
changes, vaginal bleeding in premenstrual patients, gynecomastia or precocious puberty. 
In imaging studies information was collected on the maximum solid diameter of the mass 
and flow or enhancement in a septum or solid papillary projection. We also collected 
information on flow or enhancement in a solid part of the mass was, as this information 
was available more often and has also been linked to an increased risk of malignancy in 
ovarian masses in adults.9, 10 All imaging studies were performed by radiologists or trained 
gynecologists. If necessary, the original imaging studies were reviewed by a trained 
gynecologist to collect missing information. The PRMI was calculated for each patient 
using the calculation as published by Loh et al. (Table 1). In cases where enhancement or 
flow in the solid component of the mass was present in any available imaging study, 
4 points were scored (as in enhancement or flow in a septum or papillary projection). In 
cases where an ultrasound (US) and a computed tomography (CT) or magnetic resonance 
(MR) imaging study was available, the characteristics of the mass as assessed on MR 
imaging or CT were used for purpose of this study. Patients from whom no histopathological 
data could be retrieved, were considered benign in absence of contradictory data, and 
were classified according to the final diagnosis stated by the treating physician. Patients 
were invited for follow-up visits including routine ultrasounds. Discharge of follow-up was 
depended on the nature of the mass and varied from 2 weeks to 10 years. 
Statistical analysis was performed using IBM SPSS version 20.0 statistical software. 
Continues data were analyzed using Mann Whitney U tests in case of a non-normal 
distribution. A Fisher exact test was used to analyze categorical data. The performance of 
the PRMI was evaluated using sensitivity, specificity, positive and negative likelihood, 
positive and negative predictive value and diagnostic accuracy. To visualize these results 
a ROC-curve was constructed and the area under the curve was calculated. Reported 
p-values are two-sided and results were considered significant at P < 0.05.
Table 1   Calculation of the PRMI.
Maximum diameter of largest solid component = (value in cm)
Enhancement or flow in a septum or solid papillary projection = +4
Sex hormone-related symptoms = +6
= Pediatric Risk of  
Malignancy Index score
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RESULTS
For this study 144 patients were identified, 29 patients were excluded for not meeting 
the inclusion criteria. Thirty-seven patients with incomplete records were also excluded. 
We included 78 patients in whom all data were available required for the model. 
Age ranged from 1 day to 17 years with a median age of 12 years at the time of their first 
consultation. The mass was benign in 61 (78.2%) patients and malignant in 17 (21.8%) 
patients (Table 2). In 13 (16.7%) patients there was no histological diagnosis available and 
these cases were categorized as benign. In 44 (56.4%) cases imaging studies were done 
by MR or CT, and in 34 (43.6%) cases only ultrasound data were available.
Table 2   Final diagnosis.
Final diagnosis  N (%)
Benign, non-neoplastic masses
Simple cyst
Parovarian cyst
Torsion
Auto-amputation
Pseudo cyst
Normal ovaries
Benign, neoplastic masses
Mature teratoma
Cystadenoma
Malignant masses
Immature teratoma
Dysgerminoma
Granulosa cell tumor, juvenile type
Granulosa cell tumor, adult type
Mucinous borderline tumor
Mixed germ cell tumor
Sex cord stromal tumor
39 (50.0%)
24 (30.8%)
5 (6.4%)
5 (6.4%)
3 (3.8%)
1 (1.3%)
1 (1.3%)
22 (28.2%)
18 (23.1%)
4 (5.1%)
17 (21.8%)
4 (5.1%)
4 (5.1%)
3 (3.8%)
2 (2.6%)
2 (2.6%)
1 (1.3%)
1 (1.3%)
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Table 3 shows the imaging characteristics of the benign and malignant masses. Masses 
appearing purely cystic on US were more likely to be benign (72.1% vs 23.5%, p = <0.001). 
Malignant masses presented more often as mixed or solid masses on US (41.2% vs 18.0%, 
p=0.045 and 23.5% vs 3.3%, p=0.018). There was no difference in the presence of loculation 
or an irregular cyst wall between  benign and malignant masses. Information on 
enhancement or flow in a septum or solid papillary projection was available in 65 (83.3%) 
cases and no significant differences were found between benign and malignant masses. 
Enhancement or flow in a septum, solid papillary projection or solid component was 
more common in malignant masses (64.7% vs 18.0%, p<0.001).
We calculated the PRMI for each patient and plotted the results in Figures 1 and 2. Figure 1 
shows the PRMI values of the benign and malignant masses in relation to the cut-off  
value of ≥ 7 as described in the article of Loh et al. The malignant masses scored below 
7 in 5 (29.4%) cases. The scores of benign masses ranged from 0 to 15.8, with 9 (14.8%) 
cases scoring 7 and higher. When the cut-off value of ≥7 was applied, a sensitivity of 70.1% 
(95% confidence interval (CI): 44.1-89.6%) and a specificity of 85.3% (95% CI: 73.8-93.0%) 
was found. The positive predictive value was 57.1% (95% CI: 34.0-78.1%) and the negative 
predictive value was 91.2% (95% CI: 80.7-97.0%). The positive likelihood ratio was 4.8 (95% 
CI: 2.4-9.4), and the negative likelihood ratio was 0.4 (95% CI: 0.2-0.7), indicating a moderate 
usability in clinical practice.11 Diagnostic accuracy was 82.1%. Figure 2 shows a ROC-curve, 
which displays the sensitivity and 1-specificity of the PRMI in our population. The area 
under the ROC- curve is 0.868 (CI: 0.756-0.980), which indicates a good discriminative 
power. 
Table 3   Radiological parameters.
Benign masses 
N (%)
Malignant masses 
N (%)
p-value
Size of mass on US 7.8 ± 5.5 cm 12.1 ± 5.3 cm 0.005
Cystic lesion on US 44 (72.1%) 4 (23.5%) <0.001
Mixed lesion on US 11 (18.0%) 7 (41.2%) 0.045
Solid lesion on US 2 (3.3%) 4 (23.5%) 0.018
Loculation 29 (47.5%) 9 (52.9%) 0.694
Irregular cyst wall 9 (14.8%) 5 (29.4%) 0.164
Enhancement or flow in a septum  
or solid papillary projection
6 (9.8%) 2 (11.8%) 1.000
Enhancement or flow in a septum, 
solid papillary projection  
or solid component
11 (18.0%) 11 (64.7%) <0.001
Ascites 13 (21.3%) 8 (47.1%) 0.034
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Using the ROC-curve we determined the optimal cut-off level for our population, selecting 
the cut-off level with a high sensitivity without losing too much specificity. By using a 
cut-off level of 6 the sensitivity raised to 82.4% (95% CI: 56.6-96.0%), with a slight drop of 
specificity to 80.3% (95% CI: 68.1-89.4%). The positive predictive value was 53.9%  (95% CI: 
33.4-73.4%), and the negative predictive value was 94.2% (95% CI: 84.0-98.7%). 
Figure 1   Distribution of score values of the Pediatric Risk of Malignancy Index.
A horizontal line is added to the cut off level ≥ 7.
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DISCUSSION
Main findings
In this study, the PRMI has been externally validated in a retrospective cohort study. The 
PRMI is a model to predict malignancy in ovarian masses in children, which has been 
developed by Loh et al.8 If the PRMI is able to discriminate benign from malignant masses, 
the preoperative evaluation and treatment choices in girls with an adnexal mass could be 
highly improved. Surgical approach could be adjusted to the mass being presumably 
benign or malignant.  In the original article the PRMI with a cut-off value ≥ 7 had a 
sensitivity of 90.9% and a specificity of 98.5%, which gave a positive predictive value of 
90.9% and a negative predictive value of 98.5%. With a positive likelihood ratio of 60.6 and 
a negative likelihood ratio of 0.09 this diagnostic model was very promising. 
Figure 2   Receiver-operating characteristic curve of the Pediatric Risk  
of Malignancy Index.
Diagonal segments are produced by ties. A reference line is added at 0.5. AUC = 0.868.
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Comparing our results to the results reported by Loh et al., we can conclude that the 
diagnostic value was less than in the population described by Loh et al., but overall the 
model scored well in our population. The area under the ROC-curve was 0.975 in the 
original study, and was 0.868 in the present study, which is a high repeatability and 
accuracy in an external validation study. The difference could not explained by a difference 
in population because analysis of the distribution of histology did not differ widely from 
the original study population. However, the relative high incidence of false positives in our 
population was explained by large mature teratomas with large solid components which 
by definition score high on the PRMI. Size of the mature teratomas in the population of 
Loh and co-workers is unknown so this could be a factor. The negative predictive value 
was 91.2% which makes the PRMI reliable to exclude malignancy in our population. 
However, with a positive predictive value of 57.1% the PRMI is not reliable enough to make 
management decisions regarding an ovarian mass scoring >7. By applying a cut-off level 
of 6 we tried to increase the sensitivity while maintaining specificity. With a negative 
predictive value of 94.2% the PRMI was sufficient to exclude malignancy in most of the 
benign cases with a high reliability, but with a positive predictive value of 53.9% still could 
not predict malignancy with enough certainty to make management decisions. A cut-off 
level of 6 would also imply that all sex hormone related symptoms would be enough to 
score a high probability of malignancy, which would not correlate with clinical relevance. 
To reduce the rate of false positives we would likewise recommend using a cut-off level of 
7. Information on tumor markers was available in 48 patients and we explored whether 
tumor markers would add diagnostic accuracy to the PRMI.  Unfortunately we were 
unable to increase positive or negative predictive value by adding tumor markers to the 
equation. Recent studies have questioned the usefulness of  tumor markers in the 
preoperative diagnosis of pediatric adnexal masses.12-14
Strengths and limitations
Our population was comparable in size to the population used by the authors of the 
original article to design the PRMI. Loh et al have used an Asian population, and in contrast 
our population was mostly Caucasian, with the results showing the PRMI is not directly 
influenced by race. 
To construct the PRMI we used all available imaging techniques (US, CT and MRI). While 
this could be considered as heterogenic, we chose to use the imaging technique which 
provided the most detailed information instead of using only US which was performed in 
most girls, but was also missing valuable information. Flow or enhancement was reported 
as a dichotomous variable for which we assumed the reliability to be high enough to 
allow the use of  different imaging techniques next to each other in the present study. 
Due to the retrospective nature of the study,  the availability of data on flow or 
enhancement in a septum or solid papillary formation was limited, because this is very 
specific information rarely described in standard radiology reports. We have decided to 
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substitute this variable with flow or enhancement in the solid component of the mass, 
because this information was more often available and has been proven to be present 
more often in malignant ovarian masses.15 The fact that this change into this more 
accessible variable did not impact the diagnostic characteristics of the PRMI makes the 
model even more robust and clinically useful.
Interpretation
Prediction models used in adult ovarian cancer have been validated by many researchers 
and the Risk of Malignancy Index (RMI) I, developed by Jacobs et al,16  was found to be the 
most accurate.7 The RMI I has a pooled sensitivity of 78% and a specificity of 87% in the 
systematic review of Geomini et al.7 When we compare our validation study and the 
results of Loh and co-workers to these studies we can conclude that the PRMI has 
comparable diagnostic properties as the models currently used for adult ovarian cancer. 
Both models are not reliable enough to solely base decisions on, but can be used as a tool 
in the presurgical assessment of patients with an adnexal mass to plan type of surgery. 
Ovarian cancer in adults consists mostly of epithelial tumors, which are rare in children, 
and paediatric ovarian cancer consists mainly of germ cell tumors and sex cord stromal 
tumors, which are rare in adults. This makes these risk prediction models non-interchange-
able, since their components rely on symptoms and signs specific for these particular 
types of cancer. The age cut off where the PRMI model should be changed for the RMI has 
not yet been studied. 
CONCLUSION
We can conclude that the PRMI in external validation showed less discriminative capacity 
than originally published. However, its performance is comparable with models currently 
used in adults. The PRMI can be helpful in clinical daily practice, but should not be used as 
a diagnostic test on its own until further research has proved its reliability. Therefore 
prospective studies are needed to further assess the diagnostic properties of this model, 
and to establish the value in daily clinical practice of paediatric surgery and gynecology. 
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ABSTRACT
Study question: Is ovarian cytology a reliable predictor for a malignant ovarian mass? 
Summary answer: Cytology of an ovarian mass in children and adolescents cannot be 
used to exclude malignancy.
What is known already: It is hard to predict malignancy in case of an ovarian mass in a 
child or adolescent. The most common reason to perform fine needle aspiration cytology 
(FNAC) is to exclude malignancy. Ovarian cytology has shown varying results in adults, 
but test performance is unknown in a younger population. 
Study design, size, duration: This was a retrospective diagnostic test accuracy study. 
We used the PALGA database to select girls aged 18 or younger with matching ovarian 
cytology and histology reports available between 1990 and 2014. 
Participants/materials, setting, methods: Histology diagnoses were classified according to 
the WHO classification of ovarian pathology. Cytology diagnoses were classified as benign, 
borderline malignant or malignant. Cases with inconclusive cytology diagnoses were 
excluded from analysis of diagnostic accuracy. Diagnostic accuracy was calculated using 
a 2x2 table.
Main results and the role of chance: Included were 552 girls under the age of 18 who 
had a cytology and a histology report of the same ovary available in the PALGA database. 
In 523 (94.7%) patients the mass was benign, 19 (3.4%) patients had a borderline malignancy 
and 9 (1.7%) patients had a malignant tumor. Histology diagnosis was unknown in 1 patient 
due to torsion of the ovary. Cytological diagnosis was inconclusive in 96 patients (17.4%). 
Cytology had a sensitivity of 32.0% and a specificity of 99.8%. Posttest probability of 
malignancy with positive cytology was 88.9%, the posttest probability of a malignancy 
with negative cytology was 3.8%, compared to a pretest probability of 5.5%. 
Limitations, reasons for caution: This study was retrospective, using data gathered over 
24 years. Cytology was retrieved during surgery or at the pathology department in 86.6% 
of the cases and pathologists were not blinded, which can be cause for bias. 
Wider implications of the findings: Since sensitivity is low, FNAC is not a recommended 
diagnostic tool in children. The posttest probability of a negative test compared to the 
incidence in our population resulted in a minimal difference not worth an invasive procedure. 
Study funding/competing interest(s): No study funding was received and no competing 
interests are present.
Trial registration number: NA
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INTRODUCTION
Ovarian masses in girls (defined as <18 years) are rare and in case an ovarian mass is found 
on imaging the fear of a malignancy arises. Most ovarian masses in girls are benign,1, 2 
but a test to exclude malignancy would give the surgeon the advantage of choosing 
the most optimal surgical approach and procedure. 
The risk of malignancy can be estimated using prediction models such as the criteria 
described by Papic and coworkers or the Pediatric Risk of Malignancy.2, 3 The risk of 
malignancy is known to be affected by age, menarchal status, symptoms, imaging 
 characteristics and tumur markers but studies have shown varying results and no such 
model will provide the ultimate diagnosis.2, 4 Fine needle aspiration cytology (FNAC) of 
the ovarian mass might support the assumed diagnosis before the actual surgery. 
However, the value of FNAC in preoperative diagnosis of the ovary is controversial. Results 
of various studies have been summarized by Sood and co-workers. 5 While some studies 
have shown an acceptable agreement in cytology and histology results, others clearly 
state a low sensitivity and therefore a limited usefulness in daily clinical practice. 
Results of previous studies were based on an adult population with an average age of 
40-50 years old.5-7 The ovarian histology in girls is markedly different from the histology 
found in adults, and therefore the accuracy of FNAC may be different as well. The purpose 
of this study was to determine the additional value of cytology of an ovarian mass in girls 
and adolescents in daily clinical practice. 
MATERIALS & METHODS
As primary source of this study we used the PALGA registry database, a nationwide network 
and registry of histopathology and cytopathology. This registry covers all hospitals in 
the Netherlands and contains abstracts of every histopathological and cytopathological 
diagnosis made in the Netherlands from 1990 onward.8
The primary search included all female patients of 18 years or younger with reports on 
ovarian pathology from 1991 to July 2014. Of these cases, all patients with matching 
cytology and histology reports were selected, cases with histology based solely on biopsy 
were excluded. Cytology and histology were considered matching if both reports  were 
described to be from the same ovary, no more than 180 days apart and the cytology 
report was dated before or at the same day as the histology report. Age, cytological 
diagnosis and histological diagnosis were extracted from each report. Inconclusive reports 
were reviewed by an expert pathologist, specialized in gynecologic pathology. 
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Cytological diagnoses were classified as benign, borderline malignant, malignant or 
unknown, in line with the statement of the pathologist. Histological diagnoses were 
classified according to the WHO classification of ovarian pathology, and further marked as 
benign, borderline malignant, malignant or unknown. Borderline malignant cases were 
classified as malignant in the analysis of diagnostic accuracy. Cases with insufficient 
material for cytological diagnosis or inconclusive reports (i.e. cases in which the pathologist 
was not sure or did not report on malignancy) were classified as unknown and excluded 
from analysis of diagnostic accuracy. A sensitivity analysis was performed to assess the 
effect of this exclusion, in this analysis inconclusive cytology was classified as non 
malignant, thus benign. 
Analyses were performed using IBM SPSS Statistics version 22. Graphs were designed 
using Microsoft Excel to visualize the age distribution in all cases and the cases with 
(borderline) malignancy separately. Cross tables were used to calculate sensitivity and 
specificity with corresponding 95% CI, with histology results being the reference standard.
RESULTS
The primary search resulted in 3121 reports from 1375 patients. In this group 595 patients 
(43.4%) had a cytology and histology report of the same ovary available. Thirty-five of 
these patients (5.9%) were excluded because histology was based on biopsy only, another 
eight cases (1.3%) were excluded because time between cytology and histology diagnoses 
was over 180 days, leaving 552 cases available for analysis. In 89 cases (16.1%) the cytology 
report stated ‘insufficient material available for cytological diagnoses’ and in 7 cases (1.3%) 
no information on malignancy was available in the cytology report, thus a total of 96 (17.4%) 
cases were found inconclusive (Figure 1). Time between cytology and histology ranged 
from 0-176 days and was 0 days in 479 cases (86.8%). 
 
The age ranged from 0-18 years, with a median age of 15 (Figure 2). In 523 patients (94.7%) 
the mass was benign or only normal ovarian tissue was found. Nineteen patients (3.4%) 
had a borderline malignant tumur and 9 patients (1.7%) had a malignant tumur. Malignancy 
was unknown in 1 patient because torsion caused complete necrosis of the ovary. The 
age distribution of borderline malignancies and malignancies was overall comparable to 
the age distribution of the complete population with the exception of neonates (Figure 3). 
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Figure 2   Age distribution.
Figure 3   Age distribution (borderline) malignancies.
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Histology and cytology results
The histology of the masses is listed in Table I. Cytology classified 447 lesions (82.6%) as 
benign, six lesions (1.1%) as borderline malignant and three lesions (0.5%) as malignant 
(Table II). In 96 cases (17.4%) no diagnoses based on cytology was reported, two (2.1%) of 
these were found borderline malignant and one (1.0%) was classified as malignant in the 
histology report. 
Diagnostic accuracy
The relation between cytology and histology results is shown in Table III. In 456 cases 
(82.6%) both cytology diagnosis and histology diagnoses were available. Sensitivity for 
malignancy was 32.0% with a 95% confidence interval (CI) of 15.0-53.5%, specificity was 
99.8% (95% CI: 98.7-100%). With an incidence of malignancy of 5.5% in this group, the 
posttest probability in a positive test was 88.9%. The negative predictive value was 96.2%, 
meaning the posttest probability of a malignancy in a negative test was 3.8%. 
Table I  Histological diagnoses.
Diagnosis N (%)
Benign non neoplastic pathology 118 (21.3%)
Normal ovary 11 (2.0%)
Functional cyst 85 (15.4%)
Torsion 19 (3.4%)
Other benign pathology 3 (0.5%)
Benign neoplastic pathology 405 (73.4%)
Epithelial cyst 247 (44.7%)
Fibroma/thecoma 2 (0.4%)
Mature teratoma 156 (28.3%)
(Borderline) malignant pathology 28 (5.1%)
Borderline cyst/tumor 19 (3.4%)
Malignant cystadenocarcinoma 2 (0.4%)
Malignant granulosa cell tumor 1 (0.2%)
Malignant germ cell tumor 6 (1.1%)
Unknown 1 (0.2%)
Total 552 (100%)
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In the sensitivity analysis where data from inconclusive reports were classified as benign, 
sensitivity was 28.6% (95% CI: 13.2-48.7%) and specificity was 99.8 (95% CI: 98.9-100%). 
If cases where cytology and histology were examined on the same day were excluded, 
73 cases were left for analyses. These included 2 (borderline) malignancies of which one was 
detected by cytology, resulting in a sensitivity of 50% and a specificity of 100% (Table IV). 
Table II  Cytology diagnoses.
Diagnosis N (%)
Benign 447 (81.0%)
Borderline malignant 6 (1.1%)
Malignant pathology 3 (0.5%)
Unknown 96 (17.4%)
Total 552 (100%)
Table III  Malignancy in cytological and histological diagnoses.
Histology  
(borderline)  
malignant 
Histology  
benign
Total
Cytology (borderline) malignant 8 1 9
Cytology benign 17 430 447
Total 25 431 456
Table IV  Sub analysis diagnostic cytology aspirations.
Histology 
(borderline) 
malignant 
Histology 
benign
Total
Cytology (borderline) malignant 1 0 1
Cytology benign 1 71 72
Total 2 71 73
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DISCUSSION
In this study we aimed to evaluate the value of cytological diagnoses of ovarian pathology 
in girls. We used the PALGA database to create a large database of girls with cytology and 
histology reports of the same ovary. By using the PALGA database we were able to study 
the value of cytology in a large population in the Netherlands with results comparable to 
daily clinical practice. 
We found a low sensitivity of 32.0% but a high specificity of 99.8%. While the specificity is 
outstanding, the lack of sensitivity makes cytological evaluation of ovarian masses in girls 
obsolete. When classifying inconclusive reports as benign, which was also done by Gupta 
and colleagues, the sensitivity drops further to 28.6%.9 The most common reason to 
perform cytological evaluation is excluding malignancy, which is also recommended by 
Khan et al especially in young females with clinically benign lesions.10 The present study 
shows that this is not a valid recommendation. With a low incidence of malignancy in this 
population and a low sensitivity of the test, the posttest probability of a malignancy with 
a negative test is 3.8%, compared to a pretest probability of 5.5%. We do not consider this 
small difference is worth an invasive procedure, especially in this young and vulnerable 
population. A high specificity means a low percentage of false positives, and in this study 
we show that in clinical practice this is only useful in case sensitivity is also high. Moreover, 
in 17% of cases, the cytology did not result in a diagnosis, which makes FNAC redundant 
in these cases as well.  
While borderline malignancies have overall a better prognosis than malignant ovarian 
tumurs, they can develop into invasive carcinoma.11 Therefore they cannot be classified 
as benign, and we classified borderline malignancies as malignant for the analysis of 
diagnostic accuracy in the context of this study, as is also common in adults.12  We expect 
cytology from malignant masses to contain enough cells for diagnosis, therefore 
inconclusive reports were classified as benign in our sensitivity diagnosis.
Cytology and histology reports were added to the pathology database at the same day in 
479 (86.6%) cases. This means cytology specimens were most likely taken during surgery 
or at the pathology department, meaning the pathologist who examined the specimen 
could be biased by the macroscopic appearance of the mass. Therefore our results, 
especially the sensitivity, are probably overestimating the additional value of cytology 
(meaning even better sensitivity in this study than in daily clinical practice). When cases 
with cytology and histology reports submitted to the database on the same day were 
excluded only 73 cases were left with 2 cases being (borderline) malignant. Due to the low 
incidence of (borderline) malignancies in this group further conclusions cannot be drawn 
from this analysis. 
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Recent publications have shown results comparable to the studies mentioned by Sood et 
al. The sensitivity of FNAC is often insufficient due to inconclusive results.9 Studies vary in 
methodology, with FNAC being performed before, during or after surgery and diagnostic 
accuracy calculated using multiple definitions.7, 9, 13 Diagnostic accuracy can be based on 
discrimination of nonneoplastic from neoplastic lesions or benign from malignant lesions. 
Furthermore blinding of pathologists and detailed examination including additional 
stainings is part of some studies, while in clinical daily practice these factors may be 
lacking.
FNAC is being discouraged in the ACOG practice bulletin ‘Management of Adnexal 
Masses’ as a diagnostic procedure, due to the risk of spreading tumor cells along the fine 
needle trajectory during the procedure and the poorer survival in case of intraoperative 
cyst rupture.14 In FNAC for ovarian cysts are only two cases  described with iatrogenic 
spread of malignant cells, but the spread of tumor cells has not been proven to be due to 
the FNAC procedure.15 However the integrity of the tumor capsule is a factor in tumor 
staging, upstaging a small tumor from stage IA to IC.16  Vergote and colleagues described 
a decreased 5-year survival in case of cyst rupture before or during the surgery.17 Since 
aspiration of a cyst does not leave the cyst with an intact capsule,  FNAC potentially lowers 
the 5-year survival in case of malignancies. The poor diagnostic value of FNAC combined 
with the risk to lower a patient’s survival is all the more reason to abandon this procedure.
Cases in which only cytology results were available were not included in this study. While 
we expect these patients had benign cysts, not needing further treatment, this may 
slightly have influenced our results. The sensitivity however has barely been affected by 
this decision, since sensitivity is based on the percentage of malignant masses which are 
very likely to have histology results available due to their malignant nature.
Strength of this study is the fact that we used a nationwide network and registry of 
histopathology and cytopathology, as a result of which we are sure to have identified all 
cases of girls and adolescents with cytological and histological data. Furthermore, use of 
this registry has resulted in a large and unique sample size.  
Limitations of the study are the long time period in which the data were collected which 
could have resulted in a improved accuracy over time due to better staining or training of 
the pathologists. We have assessed the change of accuracy over time, including the 
inconclusive cases. There was a difference between the early years (1990-2000) and more 
recent data (2001-2014). Sensitivity and specificity in the early period were 14.3% and 100% 
respectively, while in the recent years sensitivity and specificity were 33.3% and 99.7%. 
Even when considering the more recent data only, these results show insufficient 
additional value of FNAC to exclude ovarian malignancy in girls. In addition the data came 
from many different medical centers and pathology laboratories in the Netherlands. Data 
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could therefore be less consistent, but recommendations based on these data have a high 
external generalisability.
Ultrasound as a preoperative test has a higher diagnostic accuracy than FNAC.  Scoring 
systems like ‘Simple Rules’ provide a more reliable diagnoses without adding the risks of 
an invasive procedure.12 Considering this, the additional value of FNAC is very low. 
In conclusion, we recommend to discourage the use of  FNAC in diagnostics of ovarian 
masses in girls because it does not have additional value to exclude malignancy due to 
the low sensitivity of cytology examination, while possibly adding the risk of spreading 
malignancy.
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Adnexal masses in general, but especially in children confront every physician with 
diagnostic and therapeutic challenges. In this thesis we made an attempt to clarify the 
value of different diagnostic techniques and reported the most accurate incidence 
numbers of adnexal masses published for this patient group. We also identified factors 
related to ovarian preservation in patients with benign adnexal masses which led to some 
additional recommendations. 
In this section we discuss the relation between age, hormonal status and the risk of 
malignancy, we evaluate risk calculation methods and known risk estimation models and 
give recommendations regarding the diagnosis and treatment of girls with an adnexal 
mass. Finally we propose some ideas for future research. 
AGE, HORMONAL STATUS AND THE RISK OF MALIGNANCY
A clear relation between age and the risk of malignancy was shown in the results of chapter 2. 
Risk of malignancy is very low in neonates, than rises to reach its peak at age 6 when it 
lowers again to less than 10% at age 14. These percentages only represent cases in which 
the adnexal mass is partially or totally removed, so the percentage of malignancies at any age 
will probably be lower than in our study. This specifically applies to postmenarchal girls who 
due to their still maturing  menstrual cycle more often are diagnosed with follicle or corpus 
luteum cysts. This means age itself is not the determining factor here, but hormonal status is. 
Fetuses are influenced by maternal hormones and can therefore develop functional cysts. 
These cysts are usually found during the mid-pregnancy ultrasound scan and followed up 
after birth by a series of ultrasound scans. Maternal hormones decrease in the neonate 
which usually causes the ovarian cysts also to decrease and disappear.1 Therefore surgery 
is normally not indicated in neonates with ovarian cysts. Children in this special group 
have different normal values for alpha-foeto-protein and beta human choriogonadotro-
pin,2, 3 which are used as tumor markers for germ cell tumors.  
Premenarchal girls have a low hormonal status and therefore a lower chance of benign 
cysts, because these  grow under the influence of the menstrual cycle, resulting in a 
greater risk of malignancy in case an adnexal mass does appear. So not only age should be 
considered while assessing an adnexal mass in a girl, but also her menarchal status. 
Confusion can occur when a granulosa cell tumor induces puberty when it could be 
expected anyway, this stresses the need to take a proper history. It is important to 
distinguish the menarche from premenarchal vaginal blood loss and to consider the 
pubertal development in this context.  Although girls tend to menstruate at a younger 
age, multiple factors influence the menarche, including genetics and BMI.4 
Hormonal status can thus be divided in three groups: neonates who are still under 
the influence of maternal hormones, premenarchal girls in a low hormonal status and 
postmenarchal girls who have a menstrual cycle.
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Risk estimation & modeling
To improve current risk estimation in adnexal masses in children a new and improved risk 
estimation model is needed. The current PRMI, as designed by Loh and colleagues, is 
based on three clinical parameters; which are the maximum diameter of the largest solid 
component on imaging, enhancement or flow in a septum or solid papillary projection 
and sex-hormone related symptoms.5 It is unknown whether tumor markers, menarchal 
stage or just age could contribute to a more accurate version of the PRMI. 
The PRMI had a moderate positive predictive value (PPV) in the external validation, mainly 
caused by large mature teratomas. With addition of tumor markers and age this low PPV could 
possibly be improved, hopefully without influencing the high negative predictive value. 
The ‘Simple Rules’ from Timmerman et al can possibly help to distinguish the malignant 
masses from the benign masses.6 The simple rules combined with a subjective assessment 
of an ovarian mass  yielded the best results, comparable with a matched test performance 
of expert ultrasound examiners.7 It is however uncertain if these rules are as applicable in 
children as they are in adults.
We suggest a combination of age, menarchal status, tumor markers and the ‘simple rules’ 
as a tool for risk prediction (Figure 1: Flow diagram). Age can provide a quick pretest 
probability and is therefore a good starting point, while menarchal status is most 
important, neonatal patients deserve a different approach. Menarchal status is necessary 
to interpret the results of tumor markers and to estimate the pretest probability of the 
various adnexal masses. Tumor markers are not always applicable but seem easier to 
quantify than ‘sex hormone related symptoms’ which is used in the PRMI. The simple rules 
take cyst size, blood flow and papillary structures into account, which are also assessed in 
the PRMI, but add more variables and are better studied than the PRMI.8-10 Hereby we also 
cover the criteria which Papic and colleagues apply to distinguish a benign adnexal mass: 
size of the mass, compounds of the mass and tumor markers.  When the simple rules give 
an inconclusive diagnosis, the expert sonographer should be asked to classify the mass as 
most likely benign or malignant.
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MEASURING AND INTERPRETING TUMOR MARKERS
Neonates
Alpha-foeto protein (αFP) and beta human chorionic gonadotropin (β-hCG) are fysiologically 
high, so these tumor markers can only be defined as ‘positive’ if they exceed normal 
ranges related to age or if their decrease is not exponentially. Inhibin can be measured to 
diagnose granulosacel tumors although they are extremely rare in this population. Lactate 
dehydrogenase (LDH) can be increased in case of a dysgerminoma, these tumors can 
develop from a gonadoblastoma which occurrence is related to several genetic defects. 
Epithelial tumors are never described in this age group, so CA125 will not be helpful.
Premenarchal children
 αFP, β-hCG, inhibin, LDH and CA125 are helpful in the diagnoses of ovarian malignancies. 
LDH is not very specific and if increased other causes of a high LDH should also be 
examined first.
Postmenarchal children
αFP, β-hCG, inhibin, LDH and CA125 can be helpful in the diagnoses of ovarian malignancies. 
LDH is not very specific and if increased other causes of LDH should be examined first just 
like in premenarchal children. CA125 can also be increased in case of other gynecological 
pathology for instance endometriosis or PID, a light increase of this tumor marker is 
therefore not a certain indication of malignancy. 
IMAGING OF THE ADNEXAL MASS
Imaging characteristics of the adnexal mass play a major role in most risk estimation 
models. Ultrasonography is the preferred imaging technique for adnexal masses. Most risk 
estimation models are build to work with information from ultrasonography, including 
ultrasound Doppler to study blood flow. Depending on the chosen model different 
aspects of the mass are systematically reviewed during ultrasonography. A systematic 
approach is vital for use of the parameters in risk prediction models, but is also needed 
when collaborating and sharing information with others.  
In case more detail is needed or more information on the surroundings of the adnexal 
mass is needed to plan the surgery MRI is the technique of choice. CT can also be used in 
the diagnosis of an adnexal mass if the CT has already been performed, but should not be 
ordered specifically in case an adnexal mass is suspected.
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FINE NEEDLE ASPIRATION CYTOLOGY IN DIAGNOSTIC AND 
THERAPEUTIC CYST ASPIRATION
As described in chapter 5, FNAC should not be used as a diagnostic tool. It is an invasive 
procedure which carries not only short time risks as bleeding and infection, but also 
the long term risk of spreading malignant cells if the tumor turns out to be malignant. 
The result of cytology is also never used in risk prediction models.
In case of a therapeutic cyst aspiration; which is not recommended in most cases, cyst fluid 
should be examined for malignant cells. If malignant cells are found the mass is highly likely 
to be indeed malignant.
GENERAL RECOMMENDATIONS
1. Girls under the age of 18 with an adnexal mass should be referred to a tertiary referral 
center for diagnostic work-up and counseled by a gynecologist and a pediatric surgeon. 
2. Treatment of adnexal masses with a moderate to high chance of malignancy should 
be concentrated in a pediatric oncology center.
3. Neonates, premenarchal children and postmenarchal children have different risk 
profiles and should therefore be treated differently. 
4. Diagnosis
 a.  A history including current complaints, B-symptoms, and symptoms related to a change 
in sexual hormones should be taken.
 b. Imaging
  i.  Ultrasound is the first and preferred method of imaging. The adnexal mass 
should be described systematically, if possible by an expert ultrasonographer. 
At least size of the mass, size of the solid components, septation and papillary 
formations should be described, and the examination should include Doppler 
ultrasonography. 
  ii.  If additional imaging is necessary, MRI is preferred over CT because radiation, 
especially at young age, can induce secondary tumors.11
 c.  Tumormarkers can help to identify a malignant adnexal mass. Tumormarkers are 
different depending on the nature of the tumor. 
  i.  Germ cell tumors: alpha-foeto protein (αFP), beta human chorionic gonadotropin 
(β-hCG), lactate dehydrogenase (LDH)
  ii.  Sex cord stromal tumors: inhibin
  iii. Epithelial-stromal tumors: cancer antigen 125 (CA125) (CA19.9, CEA)
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5. Risk of malignancy should be determined based on age, menarchal status, tumor markers 
and the ‘Simple Rules’. 
 a.  Pre-test-probability of malignancy could be determined based on epidemiological 
data.
 b.  Menarchal status lowers the risk of a malignancy in case a girl is postmenarchal.
 c.  Tumormarkers can increase or decrease the risk of malignancy but are only 
supportive and not proof of a diagnosis
 d.  Imaging, more specifically ultrasound imaging, can classify an adnexal mass with 
great accuracy, if applied systematically and preferably by an expert sonographer. 
6. Surgical treatment
 a.  Surgical treatment should be done by a gynecologist and a pediatric surgeon, 
preferably  one or two surgeons in each treatment center should concentrate on 
this patient group to enhance experience.
 b.  Surgical approach should be as less invasive as possible, which means a laparoscopy 
is preferred over a laparotomy as long as it is safe.
 c.  In case of a most likely benign cyst or tumor the affected ovary should be left in situ 
and only the cyst or tumor should be removed. 
 d.  In case of suspicion of a malignancy
  i.  An oophorectomy is the designated approach, in case of a borderline malignancy 
or a suspected immature teratoma with a maximum grade 1/2 an ovarian sparing 
procedure could be justified.
  ii.  A complete inspection of the abdominal cavity including multiple biopsies 
should be done.
  iii. Spill of tumor cells should be avoided at all times
COLLABORATION & CENTRALIZATION
A multidisciplinary approach, including gynecologists as well as pediatric surgeons is 
recommended if a girl presents with an adnexal mass. Combining the extensive experience 
with young patients from the pediatric surgeon with the comprehensive experience of 
gynecologists with adnexal masses, (laparoscopic) surgery and pelvic surgery in general 
is necessary to provide these patients with high quality care. This recommendation 
especially applies to premenarchal girls, who often are referred to the pediatric surgeon 
due to their age, but also have the highest risk of malignancy. 
The low incidence of adnexal masses in children and adolescents forces us to consider 
centralization for all patients with adnexal masses who need surgical treatment. In the 
Netherlands the Princess Maxima Center for Pediatric oncology (PMC) was build to 
centralize all pediatric oncology in the Netherlands. The problem with adnexal masses in 
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children is the small percentage which is actually malignant. This would imply that the 
PMC would have to operate on approximately 80 benign ovarian tumors each year, instead 
of operating on children with actual malignancies. In addition girls with a benign adnexal 
mass would face a further travel distance and more anxiety related to the referral to an 
oncology center. 
The second option for centralization lies in the tertiary referral centers, in the Netherlands 
the university medical centers. Girls with a possible adnexal tumor should already be 
referred to these centers and when the mass seems to be benign surgical treatment could 
also take place in the center which did the diagnostic work-up.  In this case only girls with 
an adnexal mass suspicious for malignancy are referred to an actual pediatric oncology 
center. This approach demands an even more close collaboration between tertiary referral 
centers and the PMC and each center should have a dedicated pediatric surgeon and 
gynecologist to this patient group. 
FUTURE RESEARCH
Future research will focus on multiple aspects of the care for young patients with an 
adnexal mass. Clinical presentation and prognosis, local protocols, risk estimation models 
and even genetics can be subjects for further research.
A national or even international database of girls with adnexal masses including their 
symptoms and outcomes of diagnostic procedures could be helpful to better understand 
the clinical presentation of adnexal masses in this population. Former studies, including 
our own in chapter 3, have only investigated cohorts of one or sometimes a few medical 
centers while a nationwide database with clinical data could possibly reveal a lot more 
information.  If these data could also be gathered prospectively we could gain a more 
detailed and complete view of adnexal masses in girls.
Little is known about local protocols, whether formal or informal, are used in hospitals in 
the Netherlands regarding these patients. To identify the different perceptions on care 
for girls with adnexal masses we carry out a survey asking gynecologists and pediatric 
surgeons about their choices regarding the surgical treatment of adnexal masses in 
different fictive cases. The outcome of this study can be used to initiate further 
collaboration between pediatric surgeons and gynecologists and will raise awareness 
of the importance of a multidisciplinary approach.
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Malignant adnexal tumors are rare and therefore mostly described in small case series. 
Follow-up is often relatively short. With help from PALGA, the nationwide network and 
registry of histo- and cytopathology in the Netherlands, all patients in the Netherlands 
could be identified. This enables a nationwide cohort which could be followed to 
adulthood.
Application of recently developed ultrasound models for adults as the ‘Simple Rules’ in 
children has not been studied yet. It is however the best we have at the moment to 
describe adnexal masses in children systematically. Due to the different histology of 
adnexal masses in children these models may not be as accurate as in adults. To further 
study the use of ultrasound models in children a protocol with a distinct set of items to 
score should be implemented. Since the implementation of structured ultrasound 
protocols is still ongoing for adults, this study should be done in the future.
At last studying the genetic aspects of risk of malignancy in adnexal masses can open a 
new range of possibilities. Mutations in some specific genes are known to increase the risk 
of developing a  malignancy, like BRCA1/2 or DICER1, but with modern sequencing 
techniques evolving so quickly we can now screen for mutations in thousands of genes.12, 
13 Since we have a complete database of cytology and histology diagnoses in the 
Netherlands which allows us to use tissue samples nationwide,14 we could screen a large 
quantity of  ovarian malignancies in children with a broad panel of oncogenetic genes. 
Research like this could contribute to solving the puzzle on how and why ovarian 
malignancies develop at a young age.
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These flowcharts can be used in case an adnexal mass is diagnosed, due to symptoms or 
as an incidental finding, in girls under the age of 18.  
Simple rules
The Simple Rules can classify an adnexal mass as most likely benign or malignant.
Benign - Only B-features apply
Malignant - Only M-features apply
Inconclusive - no features apply, or both B- and M-features apply
Benign features Malignant features
unilocular cyst 
smooth multilocular tumur
solid component <7 mm in diameter
acoustic shadows
no detectable Doppler signal
irregular solid tumur
irregular multilocular mass >10 cm in diameter
≥4 papillary structures
ascites
high Doppler signal
Tumor markers
The following tumor markers can be helpful in diagnosing an adnexal mass and are applicable 
when using this flowchart for diagnosing adnexal masses in children:
CA-125: can be increased in epithelial tumors, only useful in premenarchal and postmenarchal 
children, these tumors are never described in neonates.
α-FP: detects germ cell tumors, is fysiologically increased in neonates, so only useful in 
diagnosing an adnexal mass in a neonate  when the level of α-FP does not decrease.
β-HCG: useful in detecting germ cell tumors, is fysiologically increased in neonates, so only 
useful in diagnosing an adnexal mass in a neonate  when the level of β-HCG does not decrease. 
An increased β-HCG can also indicate an (ectopic) pregnancy in postmenarchal girls.
Inhibin: detects granulosacel tumors
LDH: can indicate a dysgerminoma, however is a very non specific tumor marker
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SUMMARY 
In this thesis we describe the research we have performed to increase the knowledge 
about adnexal masses in girls and young women, and to come to a series of recommen-
dations in the diagnosis and surgical treatment of these patients.
In Chapter 1 we define adnexal masses as all cysts, tumors and tumor-like lesions originating 
in the ovary or the fallopian tube. Adnexal masses are known to be very rare in children but 
more common in adults. Adnexal masses can be classified as benign, borderline malignant 
or malignant, but can also be classified according to their cells of origin. We furthermore 
discuss current diagnostic techniques, from ultrasound to tumor markers, and available 
risk estimation models of which the most interesting for children is the Pediatric Risk of 
Malignancy Index. We explain different surgical techniques to treat adnexal masses and 
their implications for the future fertility of the patient. Finally we formulated a series of 
research questions.
In Chapter 2 we aimed to provide an accurate incidence of adnexal masses in children 
and women of reproductive age. We used the PALGA database, a nationwide network 
and registry of histopathology and cytopathology, to select all adnexal masses in patients 
aged 0-39. We included 11,595 patients and labeled their diagnoses as benign, borderline 
malignant or malignant and classified the mass according to the WHO classification for 
adnexal masses. We found the incidence of adnexal masses to increase exponentially 
with age, from 0.43 per 100.000 womenyears at age 1 to 152 per 100,000 womenyears 
at age 35. The histology varied widely with surface epithelial tumors (35.1%), germ cell 
tumors (29.8%), and other cysts, tumors and tumorlike lesions (32.8%) being evenly 
distributed while sex cord stromal tumors were rare and only represented 2.3%. We further 
found a relation between age and the percentage of malignancy which was highest in 
premenarchal children. 
Detailed information about diagnosis and treatment of adnexal masses in girls is described 
in Chapter 3. We retrospectively studied patients under the age of 18 diagnosed with or 
treated for an adnexal mass over the past 15 years in the Radboudumc. Multiple variables 
were studied involving symptoms and signs, diagnostic techniques, surgical procedures 
and final histology diagnosis. In total 111 patients were included with a mean age of 
10.2±5.6 years of which 28 patients (25.2%) had a malignancy. We found that surgical 
therapy was applied in 83.1% of the benign masses and comprised an oophorectomy in 
46.4%. After uni- and multivariable binary logistic regression analyses we found the 
presence of a gynecologist to be the only factor that significantly lowered to chances of 
oophorectomy in benign masses. A model to predict a benign mass, designed by Papic 
and colleagues, had a sensitivity of 40.91% and a specificity of 100%.
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In Chapter 4 we externally validated the only risk prediction model published for adnexal 
masses in children: the Pediatric Risk of Malignancy Index (PRMI). The PRMI is based on two 
characteristics of the mass on ultrasound and the presence of sex hormone related 
symptoms. In total 78 patients from the cohort of Chapter 3 were included of which all 
information needed to calculate the PRMI was available. We found a sensitivity of 70.1% 
and a specificity of 85.3%, which comes down to a high negative predictive value of 91.2% 
but a moderate positive predictive value of 57.1%. The PRMI was less accurate than 
originally published but had still a substantial diagnostic accuracy. This model can thus be 
helpful when excluding a malignancy but however cannot be used to confirm the 
diagnosis. Another diagnostic option is fine needle aspiration cytology (FNAC) which is 
described in Chapter 5. The usefulness of this technique is found to be small in adults, but 
FNAC is still used in children to exclude a malignancy. We used PALGA to identify 552 girls 
with matching cytology and histology reports, histology reports were classified according 
to the WHO classification of ovarian tumors and cytology reports were classified as 
benign, borderline malignant or malignant. We found a sensitivity of 32.0% and a 
specificity of 99.8% of FNAC in the prediction of malignancy. We do not recommend FNAC 
as a diagnostic tool in children because of the minimal difference between pretest and 
posttest probability of malignancy in benign masses.
In Chapter 6 we discuss the relationship between age and risk of malignancy.  Age as 
such is not the strongest predictor, but the relation with menarchal status was obvious. 
We also explore the options of risk estimation and modeling regarding the risk of 
malignancy in girls with an adnexal mass. Only one model is published for children, but 
multiple tools for risk estimation are available including the ‘Simple Rules’ for evaluating 
adnexal masses with ultrasonography and tumor markers. We come to a series of recom-
mendations and emphasize the need of collaboration between specialists and 
centralization of the care for young girls with adnexal masses. We also visualized and 
specified our recommendations using a flowchart. At last we explore multiple angles for 
further research; from clinical presentation to genetics.
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SAMENVATTING 
Het onderzoek dat in dit proefschrift wordt beschreven had als doel de kennis van 
adnexcystes en –tumoren bij meisjes en jonge vrouwen te vergroten en te komen tot een 
reeks aanbevelingen voor de diagnose en chirurgische behandeling van deze groep 
patiënten. 
In Hoofdstuk 1 definiëren we ‘adnexal masses’ als alle cysten, tumoren en op tumor 
gelijkende afwijkingen die ontstaan in het ovarium of de salpinx. In dit proefschrift spreken 
we in het Nederlands van adnexcystes en –tumoren. Adnexcystes en –tumoren staan 
bekend als zeer zeldzaam in kinderen maar komen vaker voor bij volwassen vrouwen. 
Adnexcystes en –tumoren kunnen worden geclassificeerd als benigne, borderline maligne 
of maligne, maar kunnen ook worden ingedeeld in typen afhankelijk van de cel waaruit ze 
zijn ontstaan. We bespreken diagnostische technieken, van echoscopie tot het bepalen 
van tumor markers, en beschikbare modellen om het risico op maligniteit te bepalen. 
De ’Pediatric Risk of Malignancy Index’ is hierbij het meest interessant. We beschrijven de 
verschillende chirurgische procedures en technieken voor het opereren van adnexcystes 
en –tumoren en hun gevolgen voor de vruchtbaarheid. Als laatste formuleren we de 
onderzoeksvragen die ten grondslag liggen aan dit proefschrift.
In Hoofdstuk 2 richtten we ons op het bepalen van de incidenties van adnexcystes en –
tumoren in kinderen en vrouwen in de fertiele levensfase. We maakten gebruik van de 
PALGA database, een databank met alle pathologie-uitslagen en een computernetwerk 
voor gegevens uitwisseling met alle pathologie-laboratoria in Nederland. We selecteerden 
alle adnexcystes en – tumoren in patiënten met een leeftijd van 0-39 jaar. We includeerden 
11.595 patiënten met een adnexcyste- of tumor en registreerden deze als benigne, borderline 
maligne of maligne. Daarnaast werden de adnexcystes en –tumoren geclassificeerd 
volgens de WHO classificatie voor ovariumtumoren. De incidentie van adnexcystes en –
tumoren bleek exponentieel toe te nemen met de leeftijd, van 0,43 per 100.000 vrouwen 
per jaar tot 152 per 100.000 vrouwen per jaar op 35-jarige leeftijd. De histologie was gelijk 
verdeeld over de groepen epitheliale tumoren (35.1%), kiemceltumoren (29.8%) en overige 
cystes, tumoren en op tumor gelijkende afwijkingen (32.8%), terwijl de sexcord stromale 
tumoren zeldzaam waren met slechts 2.3% van de totale groep. Verder vonden we ook 
een relatie tussen leeftijd en het percentage maligniteiten, deze was het hoogst in de 
groep premenarcheale kinderen.
In Hoofdstuk 3 beschrijven we de diagnose en behandelingen van adnexcystes en –
tumoren van patiënten van het Radboudumc. We bestudeerden alle kinderen onder de 
18 jaar die gediagnosticeerd waren met of behandeld waren voor een adnexcyste of –
tumor over een periode van 15 jaar. We analyseerden meerdere variabelen als symptomen, 
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diagnostische technieken, chirurgische procedure en de uiteindelijke diagnose. In totaal 
werden 111 patiënten geïncludeerd met een gemiddelde leeftijd van 10.2±5.6 jaar, 
waarvan 28 patiënten (25.2%) leden aan een maligniteit. Het grootste deel van de 
patiënten met een benigne afwijking (83.1%) onderging een chirurgische behandeling, 
waarvan 46.4% een ovariëctomie. Met uni- en multivariabele binaire logistische regressie 
analyse vonden we dat de aanwezigheid van een gynaecoloog tijdens de operatie de 
enige factor was die de kans op een ovariëctomie bij benigne afwijkingen significant 
verlaagde. Verder pasten we een model toe om een benigne afwijking te voorspellen, 
gepubliceerd door Papic et al, deze had een sensitiviteit van 40.91% en een specificiteit 
van 100%. 
In Hoofdstuk 4 valideren we het enige model dat gepubliceerd is waarmee het risico op 
maligniteit van een adnexcyste of –tumor voorspeld kan worden bij kinderen: de ‘Pediatric 
Risk of Malignancy Index’ (PRMI). De PRMI is gebaseerd op 2 karakteristieken van de cyste 
of tumor op echo en de aanwezigheid van geslachtshormoon gerelateerde symptomen. 
In totaal werden 78 patiënten van het cohort van hoofdstuk 3 geïncludeerd waarbij alle 
informatie voor het berekenen van de PRMI beschikbaar was. We vonden een sensitiviteit 
van 70.1% en een specificiteit van 85.3%, welke samen een negatief voorspellende waarde 
van 91.2% geven, maar een matige positief voorspellende waarde van slechts 57.1%. 
De PRMI was minder accuraat in onze populatie dan in de oorspronkelijke populatie 
maar had nog steeds een redelijke diagnostische waarde. Dit model kan nuttig zijn bij 
het uitsluiten van een maligniteit, maar kan een diagnose niet bevestigen. Een andere 
diagnostische mogelijkheid is een fijne naald aspiratie biopt, in internationale literatuur 
‘fine needle aspiration cytology’ (FNAC) genoemd, beschreven in Hoofdstuk 5. Het nut 
van deze techniek is beperkt in volwassenen, maar wordt bij kinderen nog af en toe 
gebruikt om maligniteit uit te sluiten. We gebruikten PALGA om 522 meisjes met cytologie 
en histologie verslagen van hetzelfde ovarium te includeren. Histologie verslagen werden 
geclassificeerd volgens de WHO classificatie voor ovariumtumoren en als benigne, 
borderline maligne of maligne. FNAC had een sensitiviteit van 32.0% en een specificiteit 
van 99.8% voor het voorspellen van een maligne ovariumtumor. We raden FNAC niet aan 
voor de diagnostiek van ovariumtumoren in kinderen wegens het minimale verschil 
tussen het pretest en posttest risico op maligniteit. 
In Hoofdstuk 6 bespreken we de relatie tussen leeftijd en het risico op maligniteit. Leeftijd 
op zich is niet de beste voorspeller, maar de relatie met menarcheale status was duidelijk 
aanwezig. We verkennen de opties voor het voorspellen van het risico op maligniteit in 
meisjes met een adnexcyste of –tumor. Slechts één model is gepubliceerd voor kinderen, 
maar meerdere modellen zijn beschikbaar voor volwassenen, zoals de ‘Simple Rules’ voor 
het beoordelen van adnexcystes en –tumoren met behulp van echo en meerdere tumor 
markers. We doen een reeks aanbevelingen en benadrukken de noodzaak van samen- 
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werking tussen de verschillende specialisten en het centraliseren van de zorg voor meisjes 
met adnexcystes en –tumoren. Om dit te specificeren en te verduidelijken hebben we 
onze aanbevelingen omgezet in een stroomdiagram. Als laatste verkennen we meerdere 
invalshoeken voor verder onderzoek, van klinische presentatie tot genetisch onderzoek.
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voor me was.
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over ons onderzoek en hielpen we elkaar weer een eindje op weg. Dankjewel voor de 
goede tijd in de tuin!
Michele, Ewout, Sasha, Judith, Jantine en Jan, van jullie heb ik geleerd hoe leuk het is om 
dokter te zijn buiten het ziekenhuis. Dankjewel!
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ook als er een tijdje weinig gebeurde of ik het zelf niet meer zag zitten. Mama, ik mis je nu 
je in het verre Engeland woont maar ik weet dat je er voor me bent. Je hebt me altijd 
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Lieve Tiemen en Jitske, bij jullie kom ik thuis. Jullie lieten mij zien dat ons leven samen nog 
veel belangrijker is dan alle onderzoeken bij elkaar. Ik houd van jullie.
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